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Ischemic vascular disease is the leading cause of morbidity and mortality 
in the United States.  Current therapies rely on invasive surgical procedures.  
Arteriogenesis, or collateral artery growth, has the potential to greatly improve 
the outcome of patients with ischemic vascular disease by providing an 
endogenous bypass circulation.  However, the underlying biology of 
arteriogenesis remains poorly understood.  There are conflicting animal and 
clinical reports of VEGF administration improving outcomes or increasing 
adverse effects.  Because of systemic VEGF’s pleiotropic functions, we 
hypothesized that local endogenous VEGF directly promotes the growth of 
collaterals.  In addition, because of its role in vascular branching morphogenesis 
we hypothesized that VEGF may also play a role in the embryonic development 
of collaterals.  To test these hypotheses, we used mouse models genetically 
targeting the VEGF pathway (VEGFhi/+, VEGFlo/+, VEGFR-1+/-, and VEGFR-2+/-) 
and local inhibitory approaches combining plasmid electroporation of Cre 
recombinase in VEGFloxP/loxP mice and FltIgG (VEGF-trap) in wild-type mice.  We 
have found that VEGFR-1 is the principle VEGF receptor responsible for 
mediating arteriogenesis through recruitment of circulating monocytes.  We also 
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found impaired arteriogenesis in mice genetically expressing low levels of VEGF 
(VEGFlo/+).  In addition, Cre-mediated deletion of VEGF in the adductor led to 
impaired plantar perfusion recovery, increased ischemic appearance, and 
impaired limb use.  Expression of FltIgG in the adductor also increased ischemic 
appearance and impaired limb use.  There was also evidence of impaired 
collateral perfusion despite normal plantar perfusion.  We found a VEGF 
genotype – collateral density relationship, such that VEGFhi/+ mice had greater 
collaterals while VEGFlo/+ mice had fewer.  Developmentally, we found that 
VEGFhi/+ and wild-type mice were born with more collaterals than VEGFlo/+.  
Interestingly in wild-type and VEGFlo/+ mice collateral density declined over the 
first 3 weeks of life at which time the adult density was attained, while VEGFhi/+ 
mice retained their collaterals from birth.  These data suggest that VEGF levels 
must be maintained high enough to establish optimal collateral density and to 
ensure maturation of nascent collaterals during development.  We identified a 
key role for VEGFR-1 in mediating collateral enlargement in ischemia.  In 
addition, we have identified the first molecule, VEGF, responsible for the 
formation of native collaterals in healthy tissue. 
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Ischemic vascular disease, including coronary artery disease (CAD), 
stroke, and peripheral artery disease (PAD), is the leading cause of morbidity 
and mortality in the United States.  PAD affects 8-12 million Americans each 
year.  Patients with PAD face a six to seven times increased risk for heart attack 
or stroke.  Many patients are unsuitable candidates for the current treatments, 
which include arterial bypass surgery or stent placement, because of 
complicating co-morbidities, such as multiple vessel occlusions.  These patients 
will often progress to gangrene or limb amputation.  Therefore, it is extremely 
important to develop alternative therapies.  One such alternative therapy is 
termed Therapeutic Angiogenesis.  The goal of this therapy is to promote blood 
vessel growth in order to re-supply ischemic tissue with oxygenated blood.  
The term Therapeutic Angiogenesis is a misnomer because angiogenesis 
(capillary growth), by itself, is incapable of restoring blood flow to ischemic tissue.  
Arteriogenesis is a unique process of vascular growth first described by Schaper 
and colleagues, which results in the growth of small arteriole-to-arteriole 
anastomoses (collateral arteries) into large conducting arteries that bypass a site 
of stenosis or complete blockage.1  Arteriogenesis requires the proliferation and 
migration of endothelial cells (EC), vascular smooth muscle cells (VSMC) and 
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pericytes; recruitment of circulating monocytes and T-lymphocytes; and 
remodeling of the extracellular matrix.2  While the mechanical and cellular 
mediators of arteriogenesis are well defined, the molecules that promote 
collateral artery growth are less well understood.  Thus, the purpose of this 
dissertation is to examine the role of one of these molecules, vascular endothelial 
growth factor-A (VEGF-A), in collateral growth in ischemic disease.  In addition, 
no studies have investigated the de novo formation of native collaterals in 
developing embryos.  We thus wanted to examine the developmental time 
course of collateral formation in healthy tissue. 
 
ARTERIOGENESIS 
There are three types of vascular growth.  In the embryo, ―vasculogenesis‖ 
is the process whereby, endothelial progenitor cells migrate and organize to form 
a primary vascular plexus.  While vasculogenesis is typically restricted to 
embryonic vessel growth, the term has been used in the adult to describe the 
incorporation of circulating endothelial progenitor cells (EPC) into growing blood 
vessels.3, 4 
After development of the primary vascular plexus, a process termed 
―embryonic angiogenesis‖ remodels the vessels into distinct tree-like structures 
that presage the final vascular architecture.  In the adult, ―angiogenesis‖ 
describes the formation of new capillaries from pre-existing capillaries.  This can 
occur via sprouting of endothelial cells from pre-existing capillary tubes or 
intussusception, whereby capillary endothelial cells extend projections into the 
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lumen to divide the capillary into multiple new vessels.5, 6   The capillary network, 
which connects proximal arterioles to distal venules is the site of nutrient and gas 
exchange. 
Arteriogenesis is a third type of vascular growth involving the enlargement, 
in diameter and length, of vessels connecting two arterioles from different, but 
parallel, arterial tress or conduits.  These unique vessels are called collateral 
arteries in that they provide an alternative, or collateral, blood supply.1, 7-14  They 
are rare in number and are thought to provide minimal nutritive flow in normal 
tissue.  However, they are extremely important when a major supply artery is 
gradually or suddenly occluded.  In diseases such as atherosclerosis, which 
progressively  narrows the lumen, coronary collaterals can significantly enlarge 
2–to–10 fold to effect an endogenous bypass of the partially occluded vessel.15  
Diseases and environmental conditions that put patients at higher risk for 
ischemic vascular disease, such as hypercholesterolemia, hypertension, 
diabetes mellitus, smoking, and aging, all negatively affect arteriogenesis.16-20 
The severity of tissue injury, ischemia and cell death following arterial 
occlusion is largely dependent on the number and diameter of pre-existing 
collaterals and their ability to enlarge over time (arteriogenesis).  Angiogenesis 
also contributes to tissue vascular adaptation to ischemia but can only function to 
better distribute whatever blood flow is provided by collaterals.  Arteriogenesis 
has been extensively studied, and mechanisms that have been defined will be 
discussed in subsequent sections of this chapter.  However, there are no data 
investigating the factors that regulate the number of collaterals that form in a 
4 
 
given tissue or individual.  It has been shown that the number of collaterals in a 
tissue is, at least in part, genetically determined.  Two inbred mouse strains have 
been identified that lie at opposite ends of the spectrum with respect to collateral 
number.21-23  Compared to BALB/c mice, C57BL/6 show a greater number of 
collaterals in skeletal muscle22, 23 and intestine.23  In addition, in the pial 
circulation that supplies the cerebral cortex, C57BL/6 have more collaterals than 
BALB/c, which have almost none.23  Genetic determination of collateral number 
(collateral density) also extends to humans.  Wustmann and colleagues 
examined 51 individuals with angiographically normal coronary arteries and no 
evidence of cardiovascular disease.  Upon transient experimental coronary artery 
balloon occlusion, they found a remarkably wide 10 fold variation in coronary 
collateral conductance wherein 20% - 25% of individuals showed high 
conductance and no evidence of myocardial ischemia whereas an equal 
percentage had low conductance and evidence of induced ischemia.  Despite the 
genetic evidence, nothing is known about the molecules that regulate collateral 
density.  One of the aims of this dissertation is to analyze VEGF-A as a possible 
regulator of collateral density. 
 
MECHANICAL MEDIATORS OF ARTERIOGENESIS 
Due to the unique position of collaterals in the circulation (ie, connecting 
two arterioles from adjacent arterial trees), these vessels normally exhibit little or 
no net directional flow.  While having not been directly measured, the pressures 
on either side of the collateral are presumed to be equal, thus providing no 
5 
 
pressure gradient to drive unidirectional flow.  Interestingly, reduced or disturbed 
flow is a hallmark of endothelial dysfunction, and vessels maintained in such an 
environment are prone to atherosclerosis and/or regression.24  However, despite 
their very altered flow environment, collaterals persist and remain patent.  The 
mechanisms that assure their persistence in normal healthy tissues are 
unknown. 
Occlusion of an artery produces a decrease in perfusion pressure distal to 
the blockage due to metabolic and myogenic dilation of distal vessels.  The 
decrease in distal pressure generates a pressure gradient across the collaterals 
that provides the driving force for unidirectional flow.  The increase in flow causes 
an increase in fluid shear stress, which is detected by endothelial cells and 
induces their activation.  Activated endothelial cells express adhesion molecules 
that bind circulating leukocytes.1, 7-12, 24-28  Leukocytes, upon diapedesis and 
migration to a peri-collateral position, then secrete growth factors, cytokines, and 
proteases to coordinate the growth of collateral arteries.1, 2, 7, 8, 10, 13, 25, 29-31 
Evidence for the importance of shear stress as the primary initiator of 
arteriogenesis comes from two studies in which blood flow across the collateral 
circulation was shunted to the venous circulation, producing chronically greater 
collateral shear stress.27, 28  In both models, an anastomosis was created 
between the femoral artery, distal to the occlusion, and the femoral vein.  This 
created an even greater increase in flow and shear across the collaterals than 
would otherwise have been observed with femoral ligation alone.  Both studies 
saw a greatly enhanced arteriogenic response such that conductance was 
6 
 
normalized.  While these studies suggest that shear stress is the limiting factor in 
arteriogenesis, the anastomoses created in these experiments also induced 
greater ischemia in the leg, which will increase circulating VEGF and thus 
complicates the interpretation of these studies. 
In addition to elevations in flow causing increases shear stress, elevations 
in blood viscosity can also directly increase shear stress.  This principle was 
demonstrated by studying mice overexpressing erythropoietin (EPO).32  
Transgenic EPO mice have a hematocrit of up to 90%, almost double that of 
wild-type, and an increase of blood viscosity of 4-fold.33  Ligation of the femoral 
artery, resulted in enhanced arteriogenesis relative to wild-type littermates.32  
Together, the above studies provide strong evidence that elevated shear stress 
is the primary stimulus of arteriogenesis.  
Despite the importance of fluid shear stress in promoting the growth of 
collaterals, it has been shown that collateral conductance and recovery of blood 
flow distal to the site of ligation never reaches pre-ligation measures.1, 9-11, 21, 23, 32, 
34  It has been proposed that circumferential wall stress (CWS) or tangential wall 
stress is a force that causes the premature cessation of collateral growth.30, 35  
Immediately after ligation, due to dilation of distal vessels and a decrease in 
downstream resistance, intravascular pressure drops in the collateral.  This 
would tend to decrease wall tension and cause reductions in wall thickness.  
However, the upstream arteries that feed the collaterals may undergo flow 
mediated dilation, which will increase the flow and input pressure to restore 
perfusion to ischemic tissues.  This will tend to counteract the decrease in wall 
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tension due to the drop in distal pressures.  Therefore, it is likely that CWS will 
change minimally as a consequence of large vessel occlusion. 
It is more probable that the normalization of fluid shear stress in the 
collateral provides the signaling break on collateral growth.  Since CWS is 
directly proportional to vessel radius and shear stress is indirectly proportional to 
the cube of the vessel radius, small increases in vessel diameter lead to more 
rapid normalization of shear stress than CWS. 
 
CELLULAR MEDIATORS OF ARTERIOGENESIS 
Schaper first described the presence of monocytes attached to the 
activated endothelium of collateral vessels.36  It has since been demonstrated 
that leukocytes are essential to collateral growth.37  Arteriogenesis is severely 
impaired in animal models chemically depleted of leukocytes.  This impairment of 
arteriogenesis can be rescued by simultaneous injection of purified isolated 
monocytes.38  Similar to the pharmacological depletion of monocytes38, genetic 
mouse models of monocyte depletion also have impaired arteriogenesis.39  
Osteopetrotic mice (op/op) have a point mutation in monocyte colony stimulating 
factor (M-CSF) resulting in secretion of non-functional M-CSF.40-42  These mice 
have monocytopenia, lymphopenia, and granulocytosis with no differences in 
circulating total leukocyte counts.  Femoral artery ligation revealed a deficit in 
arteriogenesis, perfusion recovery, and accumulation of macrophages around the 
collateral arteries.39  The above studies do not rule out a positive role for 
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lymphocytes, but clearly demonstrate the importance of functional monocytes on 
collateral artery growth. 
To determine a role for lymphocytes, Stabile and colleagues examined 
CD4-/ - mice which are deficient in CD4+ T-lymphocytes but have a normal 
complement of CD8+ T-lymphocytes and monocytes.43  Perfusion recovery was 
impaired in knock-out mice concurrent with impaired macrophage accumulation 
in ischemic tissue.43  Collateral lumen diameters were not measured; therefore 
effects on arteriogenesis cannot be conclusively determined.  The impaired 
phenotype was completely rescued by infusion of exogenously purified CD4+ 
lymphocytes.43  In a follow-up study, the role of CD8+ lymphocytes in 
arteriogenesis was tested in CD8 -/- mice.44  They found impaired perfusion 
recovery and reduced CD4+ lymphocyte recruitment to the collateral artery.  The 
phenotype was rescued by administration of exogenous CD8+ lymphocytes or IL-
16 at the time of ligation.44  Together, the data suggests that early on in 
arteriogenesis, CD8+ lymphocytes are first recruited to collaterals where they 
secrete cytokines, such as IL-16, to recruit CD4+ lymphocytes that in turn recruit 
monocytes and that all cell types are necessary for proper collateral growth.  
While it has been shown that purified leukocytes can secrete a variety of growth 
factors and cytokines in vitro, it is not known what molecules are responsible for 
the promotion of arteriogenesis in vivo. 
In addition to recruited cell types, resident cells are also critical for 
arteriogenesis.  Endothelial cells respond to the shear stress stimulus and  
express adhesion molecules on their lumenal surface.  While the shear stress 
9 
 
sensing mechanism and endothelial responses to shear have been extensively 
studied in vitro,45, 46 it is not known if these same mechanisms act in vivo in 
collaterals.  Proper growth and migration of vascular smooth muscle cells are 
also required to accommodate the increased forces exerted on the collateral wall 
following vessel occlusion.  One of the most potent arteriogenic molecules, 
monocyte chemotactic protein-1 (MCP-1), is a smooth muscle cell mitogen in 
addition to its role in recruiting circulating monocytes.  Other stimulators of 
smooth muscle growth and migration need to be elucidated to design optimal 
therapies to promote arteriogenesis.  The collateral adventitia also extensively 
remodels during arteriogenesis and may provide a resident source of progenitor 
cells to contribute to the growth of collaterals.9, 47, 48 
 
MOLECULAR MEDIATORS OF ARTERIOGENESIS 
Most of the molecules examined have been growth factors or 
chemo/cytokines.  To date, the most potent arteriogenic cytokine is MCP-1.  
Exogenous administration of MCP-1 at the time of ligation greatly enhances 
monocyte recruitment and collateral growth.49-51  Similarly, in genetic mouse 
models of MCP-1 or CCR2 (MCP-1 receptor) deletion, arteriogenesis is 
inhibited.52, 53  Interestingly, the actions of MCP-1 may, in part, be mediated by 
VEGF.54, 55  Inflammatory molecules such as TNF-, which increase the 
mobilization and recruitment of leukocytes, are also strong arteriogenic 
cytokines.56  Toll-like receptor-4 has been shown to be important in outward 
remodeling of arteries57; however its role in arteriogenesis has not been 
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examined.  Leukocytes, while important, are ineffective unless they can interact 
with the collateral endothelium and transmigrate through the vascular wall.  Thus, 
as expected, adhesion molecule expression is critical in mediating collateral 
artery growth.58, 59 
Tyrosine kinase receptors are essential for arteriogenesis.  Systemic 
inhibition with a non-selective protein tyrosine phosphatase inhibitor enhanced 
collateral blood flow in a rat model of peripheral vascular disease.60  In vitro, 
these investigations observed enhanced signaling from VEGFR-2 and Tie-2, 
receptors for VEGF and Ang-1 respectively.60  Studies administering VEGF61-75 
or Ang-176 either singly or in combination77, 78 have shown enhanced 
arteriogenesis and collateral perfusion.  Placental growth factor (PlGF), which 
belongs to the VEGF family of proteins, has also been shown to be a positive 
modulator of arteriogenesis.79, 80  Platelet derived growth factor-B (PDGF-B)81, 82, 
basic fibroblast growth factor (bFGF)81, 83-92, and hepatocyte growth factor 
(HGF)93 are other growth factors demonstrated to augment collateral growth of 
tissue perfusion. 
The extracellular matrix (ECM) is a complex structure surrounding 
collaterals.  It provides support for the collateral artery and may also provide a 
reservoir of growth factors for the stimulation of arteriogenesis.94  Many of the 
growth factors listed above have protein domains which confer ECM binding 
affinity.  Components of the ECM also have angiostatic properties.95  The role of 
these molecules has not been studied with respect to arteriogenesis.  In order for 
the collateral to enlarge in length and diameter, it is necessary for the ECM to 
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remodel to accommodate the growing collateral.  Matrix proteases such as MMP-
2 have been shown to become activated in angiogenesis, but a role in 
arteriogenesis has yet to be determined.  
 
VASCULAR ENDOTHELIAL CELL GROWTH FACTOR 
Vascular endothelial growth factor (VEGF), or vascular permeability factor 
(VPF), was originally isolated as a secreted cytokine that increased permeability 
in tumor vessels.96  It was subsequently identified as an endothelial specific 
mitogen.97, 98  In endothelial cells, VEGF is also a potent chemotactic agent and 
pro-survival factor.99  VEGF is also a potent vasodilator due to its downstream 
activation of endothelial nitric oxide synthase (eNOS) and subsequent nitric oxide 
production.100-102  In addition to its actions on endothelial cells, VEGF also acts 
as a pro-migratory, anti-apoptotic, and survival factor in numerous other cell 
types, including skeletal muscle103-106, vascular smooth muscle107, 108, and 
monocytes109, 110. 
In mice, VEGF mRNA is alternatively transcribed into three major 
isoforms, VEGF120, 164, and 188.  The high molecular weight isoforms, 
VEGF164 and VEGF188, contain heparin-binding motifs, which establish a 
distribution of the growth factor.  In contrast, VEGF120 lacks this motif assigning 
it diffusible and circulating activities.  The differential splicing mechanism 
regulating which isoforms are produced is not clear, however each isoform is 
biologically and functionally unique.  Mice that lack the heparin binding isoforms 
have impaired vessel branching morphogenesis and larger caliber vessels.  
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Conversely, mice that express only VEGF188, contain an excess of endothelial 
cell filopodia and vessel branching.111  Evidence from this and subsequent 
studies using targeted mice demonstrate that all three isoforms are critical to 
establish the proper VEGF gradient in tissues to allow correct development and 
patterning of the vasculature and related organs. 
VEGF-A acts through two high-affinity receptor tyrosine kinases, VEGFR-
1 (flt-1) and VEGFR-2 (flk-1/KDR).  Numerous studies have demonstrated that 
the VEGF signaling cascade is primarily mediated by VEGFR-2.  In embryonic 
development, VEGFR-1 is thought to act predominantly as a negative regulator 
of VEGF signaling through the alternate transcription of a soluble VEGFR-1 
antagonist.  Because of its weak kinase activity, it has been difficult to dissect 
any signaling pathway mediated by VEGFR-1.112  However, recent experiments 
in adult mice using the VEGFR-1 specific agonist PlGF and targeted mice lacking 
the kinase domain of VEGFR-1, demonstrate a positive role for VEGFR-1 
signaling.109, 113  VEGFR-2 is primarily expressed on endothelial cells, but it also 
can be found on a sub-population of bone marrow derived cells termed 
endothelial progenitor cells (EPCs).  VEGFR-1 is expressed on endothelial cells 
but also on vascular smooth muscle cells, skeletal muscle, and on T-lymphocytes 
and monocytes where it acts as a chemotactic receptor.107, 110 
    
SOURCES AND ACTIONS OF VEGF-A IN THE COLLATERAL ZONE 
The microenvironment surrounding collateral vessels contains numerous 
other cell types that may be influenced by actions of VEGF.  In an in vitro co-
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culture system, VEGF stimulated migration and proliferation of aortic smooth 
muscle migration in an endothelial cell-dependent manner.108  Interestingly, 
VEGF also mediates MCP-1 induced smooth muscle migration and proliferation55 
and angiogenesis54.  To date, MCP-1 is the most potent factor mediating 
collateral artery enlargement.  In skeletal muscle, VEGF is a pro-survival 
molecule that also stimulates migration of skeletal myoblasts in culture.103  In 
damaged muscle tissue, exogenously delivered VEGF promotes the growth and 
survival of myogenic fibers.104  In a further adaptation to a hypoxic stimulus, 
VEGF stimulates the expression of myoglobin, thus greatly increasing oxygen 
carrying capacity in ischemic skeletal muscle.105  VEGF also affects circulating 
cell types.  It acts on receptors on cells from the hematopoetic lineage to 
increase proliferation and mobilization of leukocytes.114  VEGF stimulates the 
expression of adhesion molecules such as, vascular adhesion molecule-1 
(VCAM), intercellular adhesion molecule-1 (ICAM-1), and E-selectin in 
endothelial cells, which facilitates the recruitment and diapedesis of leukocytes, 
including monocytes, neutrophils, and T-lymphocytes.115 
Collateral and peri-collateral cells are also potential sources of VEGF in 
addition to responding to VEGF.  Efforts to quantitate tissue VEGF have been 
complicated by the relatively low abundance of endogenous VEGF in the adult 
and the complex milieu surrounding the collateral arteries.  Current antibodies 
used for Western blot analysis are unable to distinguish between the various 
isoforms of VEGF.  While qRT-PCR is used to distinguish the relative 
contribution of each isoform in a tissue, no such studies have been done in the 
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context of collateral artery growth (Chapter 2 and 3).  It is likely that increases in 
VEGF production, if any, will be limited to the region immediately surrounding the 
collateral (Chapter 3).  No studies have described the cellular expression pattern 
of VEGF or its receptors in the collateral and peri-collateral region.  A study by 
Couffinhal and colleagues described the identity of VEGF producing cells in a 
mouse hindlimb ischemia model.  In ischemic lower limb muscles, VEGF 
secretion was markedly upregulated in skeletal muscles up to day 14 post-op, 
with expression decreasing up to 35 days post-op.  In addition, VEGF 
immuoreactivity was seen in macrophages and T-lymphocytes in the ischemic 
lower limb.  The authors also identified VEGF mRNA and protein expressed in 
endothelial cells of the ischemic lower limb.116  Whether or not these cell types 
also express VEGF in the collateral region has not been examined (Chapter 2 
and 3). 
Skeletal muscle is potentially the largest source of VEGF in the collateral 
microenvironment.  Despite the lack of detectable hypoxia in this region117, VEGF 
could be upregulated by mechanical stimulation of the muscle.  Increases in 
mechanical load and capillary shear stress, which could occur in the thigh in 
models of PAD, lead to increases in skeletal muscle VEGF secretion and 
capillary density.118  Ischemic lower limb muscles, which are far removed from 
collateral vessels, are potentially the largest source of circulating VEGF.  Plasma 
VEGF may then stimulate proliferation and mobilization of leukocytes from bone 
marrow.  Targeted deletion of skeletal muscle VEGF leads to muscle apoptosis 
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and a decrease in capillary density, stressing the importance of even basal 
skeletal muscle VEGF in the maintenance of the tissue.119 
Vascular wall cells are an additional source of VEGF.  Skeletal muscle 
capillary endothelial cells express increased amounts of VEGF in response to 
increased capillary shear stress, which could occur in the thigh in resonse to 
flow-mediated dilation upstream of collaterals after femoral ligation..26  Shear 
stress and stretch have been shown to increase the expression and activation of 
VEGFR-2 in endothelial cells, thus providing a local autocrine positive feedback 
loop.120, 121  Vascular smooth muscle cells are a third source of VEGF.  In vitro, 
smooth muscle cells increase expression of Hif-1 and VEGF in response to 
cyclic mechanical stretch.122 
Cells recruited to remodeling collateral vessels are also potential sources 
of VEGF production.  In vitro studies demonstrate that bone marrow-derived cells 
can secrete large amounts of VEGF.123  Local injection of these cells into the 
collateral zone shows co-localization of VEGF.  However, whether this VEGF 
contributes to collateral growth has not been clearly defined.  An important aim of 
this dissertation is to analyze the role of local paracrine VEGF signaling in 
collateral growth in ischemia. 
 
VEGF-A IN ARTERIOGENESIS 
Human trials and animal studies using exogenous VEGF to promote 
arteriogenesis have met with mixed results.61-75, 117, 124-127  The complex biology 
of VEGF128 (ie, multiple isoforms, receptors, and actions) and the complex nature 
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of the collateral microenvironment, make it difficult to assess the effect of 
exogenously delivered VEGF on collateral artery growth.  Studies have shown 
that increases in VEGF expression correlates with increases in capillary density 
but not with increases in angiographic score.129  The authors concluded 
therefore, that VEGF was not a mediator of arteriogenesis.  However, the 
biological mechanism of angiogenesis and arteriogenesis are distinct.  Therefore 
it is incorrect to assume that VEGF has similar temporal properties in these two 
processes.  In addition, the method used by these investigators to detect VEGF 
does not distinguish between the isoforms.  It is likely that the amount and 
localization of an isoform, rather than the total amount of all isoforms, is 
important in collateral growth.  In a subsequent study, Hershey and colleagues 
delivered adenovirus encoding human VEGF165 to the thigh of rabbits and failed 
to show improvement of the angiographic score.124  They were only able to elicit 
a transitory increase in VEGF expression lasting from 3 to 5 days depending on 
the viral dose.  In addition, the timing of injection was 10 days post-ligation.  The 
events that initiate collateral remodeling begin immediately ligation21, thus it is 
possible that events already set into motion may not be susceptible to further 
augmentation by later administration of VEGF.  Moreover, higher doses of 
adenovirus-VEGF165 induced edema in the upper hindlimb.124  This edema, 
which suggests that the level of VEGF was too high, could have reduced flow in 
the collaterals and therefore prevented growth of the collaterals.  
Developmentally, VEGF is regulated in a narrow window of expression such that 
overexpression or underexpression is embryonic lethal.130-133  Likewise, it is 
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possible in the adult that VEGF has a narrow therapeutic window, such that too 
much leads to edema and no collateral remodeling and too little has no effect at 
all. 
In contrast, several reports support a role for VEGF in arteriogenesis.  
Delivery of plasmid encoding VEGF165 intramuscularly or intraarterialy67, 70 
reportedly increases angiographic score, calf blood pressure ratio, and flow.  
Importantly, plasma VEGF and arterial pressure were not measured.  If VEGF 
were released systemically from the transfected tissue, it could have caused 
systemic vasodilation, including in the ligated limb which would favor increased 
flow in collateral circulation and collateral growth.  This effect would be 
secondary to VEGF’s systemic actions and not a direct effect of VEGF on 
collateral vessels.  This limitation holds true for all studies that deliver VEGF 
systemically.  In addition, systemically released VEGF could further confound the 
interpretation of direct actions on the collateral vasculature by augmenting 
angiogenesis in the lower limb, distal to the ligation, and thus potentially alter the 
hemodynamics in a way favorable for collateral growth.  Furthermore, systemic 
VEGF release could increase the mobilization of bone marrow derived cells, thus 
augmenting leukocyte chemotaxis to the collateral vessel and increasing their 
positive role in collateral growth. 
The above makes clear that systemic VEGF delivery can lead to 
complications in the interpretation of VEGF’s direct role in collateral growth.  An 
alternative approach is to block the actions of endogenous VEGF and study its 
affect on collateral growth.  To this end, three groups have demonstrated that 
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blockade of VEGF greatly impairs collateral growth in hindlimb134, 135 and 
myocardial ischemia models136.  However, like systemic delivery of VEGF, 
systemic blockade can also confound the interpretation of any direct role.  
Systemic inhibition has the potential to increase peripheral resistance by the 
removal of a potent vasodilator.  This in turn could result in a decrease in flow 
and shear stress in the collaterals thus preventing a powerful stimulus of growth 
in the collateral arteries.  Systemic inhibition might also block mobilization and 
recruitment of leukocytes, negating their role in collateral growth.  Systemic 
blockade could also inhibit angiogenesis in the ischemic tissue, creating greater 
ischemia and tissue damage.  This is especially important in the coronary 
collateral circulation, where the ischemic myocardium overlaps the collateral 
zone.  Edema from ischemic tissue damage could block arteriogenesis 
irrespective of VEGF’s actions.  To elucidate VEGF’s direct contribution to 
collateral growth, it is necessary to block VEGF’s actions only in the collateral 
zone  (Chapter 3).  It is also important to develop strategies for local disruption of 




   
CHAPTER 2 
Vascular Endothelial Growth Factor-A 




The density of native (pre-existing) collaterals and their capacity to enlarge 
into large conduit arteries in ischemia (arteriogenesis) are major determinants of 
the severity of tissue injury in occlusive disease.  Mechanisms directing 
arteriogenesis remain unclear.  Moreover, nothing is known about how native 
collaterals form in healthy tissue.  Evidence suggests VEGF, which is important 
in embryonic vascular patterning and ischemic angiogenesis, may contribute to 
native collateral formation and arteriogenesis.  Therefore, we examined mice 
heterozygous for VEGF receptor-1 (VEGFR-1+/-), VEGF receptor-2 (VEGFR-2+/-), 
and over-expressing and under-expressing VEGF-A (VEGFhi/+ and VEGFlo/+).  
Recovery from hindlimb ischemia was followed for 21 days after femoral artery 
ligation.  All statements below are p<0.05.  Compared to wild-type mice, VEGFR-
2+/- showed no deficits in recovery of hindlimb perfusion, collateral enlargement 
or angiogenesis, and ischemic scores were comparable.  In contrast, VEGFR-1+/- 
showed reduced recovery of perfusion, reduce collateral enlargement and worse 
ischemic scores, whereas angiogenesis was comparable.  Compared to wild-
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type mice, VEGFlo/+ had 2-fold lower perfusion immediately after ligation 
(suggesting fewer native collaterals which was confirmed by angiography) and 
blunted recovery of perfusion.  VEGFhi/+ mice had 3-fold greater perfusion 
immediately after ligation, more native collaterals, and improved recovery of 
perfusion.  These differences in collateral density were confirmed in the cerebral 
circulation; compared to wild-type mice, VEGFlo/+ formed fewer and VEGFhi/+ 
formed more collaterals during the perinatal period during which adult density 
was established.  Our findings indicate VEGF and VEGFR-1 are determinants of 
arteriogenesis.  Moreover, they identify VEGF as the first signaling molecule 
specifying formation of native collaterals in healthy tissues.  
 
INTRODUCTION 
Ischemic vascular disease is the leading cause of morbidity and mortality 
in the developed world.25  The number and diameter of native (pre-existing) 
collaterals in a healthy tissue and their capacity to enlarge (remodel) are critical 
determinants of the severity of ischemic injury following arterial obstruction.  
While molecules regulating collateral remodeling in ischemia are beginning to be 
understood,8 nothing is known regarding when native collaterals form or the 
responsible signaling mechanisms.29 
Collateral enlargement in ischemia requires proliferation of endothelial 
cells, leukocyte recruitment, proliferation and migration of mural cells, and 
remodeling of the extracellular matrix.  Evidence suggests VEGF participates in 
each of these processes.137  However, trials testing whether exogenous VEGF 
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can augment collateral enlargement have met with mixed results.25  The 
complexities of VEGF signaling (ie, multiple isoforms, receptors and intracellular 
pathways) plus the inaccessibility of the collateral circulation make it difficult to 
determine a direct effect on collateral remodeling.  Most studies have 
administered a single VEGF isoform with limited control of concentration, leading 
to defective neovascularization, tissue edema and impaired vessel growth.138  
Recent studies have shown that multiple gradient-forming isoforms are 
expressed within narrow concentration windows that, if exceeded too greatly in 
either direction, lead to aberrant vessel formation, embryonic lethality and 
disturbed vessel maintenance and growth in the adult.130-133, 139  Interestingly, 
administration of an engineered zinc-finger transcription factor that drives 
expression of multiple VEGF isoforms improved recovery of limb perfusion 
following femoral artery ligation.140, 141 
While the above studies examined therapeutic VEGF, findings from 
several studies using VEGF antagonists given systemically suggest that 
endogenous VEGF may contribute to ischemic collateral remodeling.134-136  
However, no study has examined this question with a genetic approach or 
identified the responsible VEGF receptor type.  VEGF acts primarily through two 
high-affinity receptor tyrosine kinases, VEGFR-1 (flt-1) and VEGFR-2 (flk-
1/KDR).  VEGF-induced angiogenesis is mediated predominantly by VEGFR-2.  
However, during embryonic development alternately transcribed soluble VEGFR-
1 (sFlt-1) also participates as a negative regulator of VEGF signaling.137, 142  
Because of weak kinase activity, it has been difficult to clarify potential signaling 
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by membrane-anchored VEGFR-1.  However, experiments in adult mice using 
the VEGFR-1 specific agonist, PIGF, and targeted mice lacking the kinase 
domain of VEGFR-1 demonstrate a positive role for VEGFR-1 signaling.80, 113  In 
this study, we examined the effect of targeted over- and under-expression of 
VEGF, VEGFR-1 and VEGFR-2 on collateral remodeling in ischemia. 
It is not known when the native collateral circulation develops or what 
signaling pathways specify formation of these rare vessels that interconnect 
adjacent arterial trees through artery-to-artery anastomoses.  A previous study in 
our laboratory identified two inbred mouse strains —C57BL/6 and BALB/c— that 
differ in collateral density (BALB/c are markedly deficient), and identified an 
expression quantitative trait locus at or near Vegfa that positively correlated with 
low VEGF expression at the BALB/c allele.23  Thus in the present study, we also 
tested the hypothesis that VEGF expression is a determinant of collateral 
formation in newborn and adult mice genetically targeted to over- and under-
express VEGF. 
 
MATERIALS AND METHODS 
Unilateral hindlimb ischemia.  Twelve-to-16 week-old VEGFR-1+/-, 
VEGFR-2+/-, VEGFhi/+ and VEGFlo/+ mice131, 143-145 (kindly provided by J Rossant 
and A Nagy), maintained on the CD-1 background and genotyped by X-gal 
staining of tail biopsies, were compared to wild-type littermate controls.  Animals 
were randomized and procedures and analyses were conducted blindly.  
Femoral artery ligation was performed as described.23, 34  Briefly, mice were 
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anesthetized with 1.25% isoflurane/O2 and the hindlimbs depilated.  Temperature 
was maintained at 37.0±0.5ºC.  The right femoral artery was exposed through a 
2mm incision and ligated with two 7-0 ligatures placed distal to the origin of the 
lateral caudal femoral and superficial epigastric arteries (the latter was also 
ligated) and proximal to the genu artery.  The artery was transected between the 
sutures and separated by 1-2 mm.  The wound was irrigated with sterile saline 
and closed, and cefazolin (50mg/kg, im), furazolidone (topical) and pentazocine 
(10mg/kg, im) were administered.  Procedures were approved by the University 
of North Carolina Institutional Animal Care and Use Committee.    
Laser Doppler perfusion imaging.  As detailed previously,23, 34 under 
1.125% isoflurane/O2 anesthesia and 37±0.5ºC, non-invasive perfusion imaging 
of the adductor thigh region and plantar foot of both limbs was performed before, 
immediately after, and at 3, 7, 14, and 21 days after femoral ligation.  Regions of 
interest were drawn to anatomical landmarks.   
Assessment of ischemia.  An ―appearance score‖ after ligation was 
obtained, where 0=normal, 1=cyanosis or loss of nail(s), 2=partial or complete 
atrophy of digit(s), 3=partial atrophy of fore-foot.23 
Leukocyte counts.  Three days after femoral ligation blood was collected 
under anesthesia by retro-orbital puncture.  Leukocyte counts were performed 
with a Heska’s Animal Blood Counter. 
Histology.  21 days after ligation, animals were pressure-perfused 
transcardially (100mmHg) with phosphate-buffered saline (PBS, pH7.4) 
containing 20mmol/L adenosine, 10-4mol/L papaverine and 10U/ml heparin, 
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followed by pressure-perfused fixation with 4% paraformaldehyde in 100mmol/L 
sodium phosphate (PFA; pH7.4) for 15min.  The adductor below the femur was 
excised in a 5mm block extending ~1mm medial of the ―mid-zone‖ of the gracilis 
muscle collaterals that interconnect the lateral caudal femoral artery and 
saphenous artery trees, to the lateral portion of the thigh.  A 5mm block of the 
calf was excised beginning at the origin of the Achilles tendon.  Blocks were 
paraffin-embedded and sectioned at 5µm.  Lumen diameter of collaterals in the 
anterior and posterior gracilis muscles was determined from sections of their mid-
zone stained with cyano-Massons trichrome.  For all histochemical analyses, 
results reported for each animal were averages of values from two sections 
separated by 250µm.  Griffonia Simplicifolia isolectin-1-B4 (Vector Labs) was 
used to determine capillary density and capillary-to-muscle fiber number in two 
40x fields from the posterior head of gastrocnemius muscle.  Leukocyte density 
around gracilis collaterals was determined with CD45 (BD Pharmingen) 
immunohistochemistry.23, 34 
Post-mortem arteriography.  As detailed previously,23 animals were 
maximally dilated and perfusion-fixed 7 days after ligation when the contralateral 
femoral artery was also ligated.  A high-viscosity barium sulfate solution 
(85%w/v) with impaired capillary transit was infused after ligation of the ankles to 
minimize arterial-venous shunting, followed by X-ray angiography.  A Rentrop-
like line analysis was performed on digitized films by counting vessels 
intersecting a line drawn perpendicular to the femur beginning at a point distal to 
the femoral ligation that approximated the midpoint of the gracilis collaterals.  
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Cerebral pial arteriography was obtained in separate groups following maximal 
dilation and perfusion-fixation.23  After removal of the dorsal calvarium, high-
viscosity polyurethane146 (60% resin in 2-butanone with blue dye) that is unable 
to cross capillaries was infused via the thoracic aorta during stereoscopic 
imaging, followed by topical and the whole-brain fixation in 2% PFA overnight at 
4ºC.  Brains were imaged and collaterals interconnecting the middle and anterior 
cerebral artery trees were counted.23 
Quantitative RT-PCR.  The hindlimbs were perfused 36h after unilateral 
femoral artery ligation with RNA-later (Ambion) via that abdominal aorta under 
deep anesthesia. 5mm thick sections of proximal calf and the adductor centered 
on the collateral mid-zone and perpendicular to the femur were excised and 
stored in RNA-later at -80ºC.  Tissue was pulverized under liquid nitrogen.  Total 
RNA was extracted (RNeasy Fibrous Tissue mini kit, Qiagen) according to the 
manufacturer.  Genomic DNA was removed by on-column DNase treatment 
(Qiagen).  Total RNA was reverse-transcribed (Verso cDNA kit, Abgene).   Real-
time PCR was performed with triplicate cDNA samples diluted 1:100 using SYBR 
Green chemistry (Sigma) on a Rotor-Gene 3000 (Corbett Life Science).  Data 
were analyzed according to the Pfaffl method.147 
Statistics.  All data are reported as means ± SEM.  Significance (P<0.05) 
was determined by two-way ANOVA followed by Dunn-Bonferonni Corrected t-
tests.  One-way ANOVA was used for comparisons between VEGF genotypes 
(VEGFhi/+, VEGFlo/+, wild-type), followed by paired or un-paired t-tests.  Capillary 
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number-to-muscle fiber ratios and appearance scores were subjected to Mann 
Whitney U tests. 
 
RESULTS 
Reduced recovery after femoral artery ligation in VEGFR-1 heterozygous mice. 
Although VEGFR-1-/- or VEGFR-2-/- mice are embryonic lethal, mice 
heterozygous for the receptors have defects in cardiac preconditioning but 
otherwise appear normal.148, 149  We examined VEGFR-1+/- and VEGFR-2+/- mice 
for recovery from femoral ligation.  Compared to wild-type, VEGFR-1+/- had larger 
paw appearance scores indicating greater ischemia23 (Fig. 2.1a).  In contrast, 
VEGFR-2+/- showed no differences (Fig. 2.1b).  In agreement, recovery of plantar 
perfusion (Fig. 2.1c), which correlates with overall hindlimb blood flow34, was 
attenuated in VEGFR-1+/- but not in VEGFR-2+/- mice (Figs. 2.1d,e). 
To investigate the responsible mechanisms, we measured capillary 
density in gastrocnemius muscle.  While capillary-to-muscle fiber number ratios 
at baseline were comparable among groups, ratios significantly increased at day-
21 in VEGFR-2+/-, and trended similarly in VEGFR-1+/- mice. (Figs. 2.2a,d,g).  
The increase in VEGFR-2+/- was associated with slightly greater capillary area 
density and muscle atrophy (Suppl. Figs. 2.1b,f).  Capillary area density and 
muscle atrophy were not different in VEGFR-1+/- (Suppl. Figs. 2.1a,e).  We next 
examined collateral diameters in the anterior and posterior gracilis muscles and 
perfusion in the superficial adductor region containing these collaterals.  Lumen 
diameter was not different at baseline among groups.  However, outward 
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remodeling at day-21 was less in VEGFR-1+/- (p=0.07, 2-tailed) (Figs. 2.2b,e,h).  
In addition, VEGFR-1+/- had reduced adductor perfusion (Suppl. Fig. 2.2d).23, 34  
Collateral remodeling and perfusion were not different in VEGFR-2+/- mice (Fig. 
2.2h, Suppl. Fig. 2.2e).  Leukocytes contribute importantly to collateral artery 
growth.8, 25, 29  Peri-collateral CD45+ leukocytes were not different in VEGFR-2+/-, 
but were reduced in VEGFR-1+/- mice (Figs. 2.2c,f,i), consistent with their 
attenuated collateral remodeling.  In addition, circulating leukocytes, 
lymphocytes, and monocytes were lower three days after ligation in VEGFR-1+/- 
(Suppl. Table 2.1).  These findings indicate that reduced expression of VEGFR-
1 results, after femoral artery occlusion, in fewer circulating and peri-collateral 
leukocytes, reduced collateral enlargement and flow, reduced recovery of 
hindlimb flow, and greater tissue ischemic injury.  They suggest VEGFR-1 is 
important in collateral remodeling. 
 
The VEGF hypermorphic allele augments —and hypomorphic allele attenuates—  
recovery after femoral artery ligation. 
Studying the role of endogenous VEGF levels has been difficult because 
heterozygous and homozygous null mice are embryonic lethal.  Thus, VEGF-A 
reporter mice have been constructed to generate hypermorphic or hypomorphic 
alleles.130, 131, 145  Homozygosity of either allele results in embryonic lethality due 
to excess or insufficient VEGF.  However, VEGFhi/+ and VEGFlo/+ are viable and 
appear normal despite expressing VEGF at intermediate levels to homozygous 
and wild-type counterparts.130, 131  Since data are not available, we assessed 
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expression of the VEGF isoforms, VEGF120, VEGF164, and VEGF188, by qRT-
PCR in calf and collateral zone adductor muscles. 
Baseline VEGF expression in calf muscle from the non-ligated leg was 2-
fold higher in VEGFhi/+ and 25-75% lower in VEGFlo/+ compared to wild-type 
(Suppl. Fig. 2.3a).  Thirty-six hours after femoral ligation, expression in the calf 
increased in all three strains for VEGF120 (Figs. 2.3a-c).  In contrast, expression 
in the adductor of the ligated leg, which does not experience detectable ischemia 
in this model,117 showed selective upregulation of the high-molecular weight 
isoforms, VEGF-164 and -188, in wild-type and VEGFhi/+ mice (Figs. 2.3d,e).  
Interestingly, all VEGF isoforms decreased in the VEGFlo/+ mice (Fig. 2.3f).  To 
determine involvement of HIF signaling in this unique pattern of upregulation in 
the adductor collateral zone, we performed qRT-PCR for Hif-1, Hif-1 and Hif-
2.  Whereas expression was similar in all strains in the non- ligated leg’s 
adductor (Suppl. Fig. 2.3b), Hif-1 increased 2-fold while Hif-1 was unaffected 
in the ligated leg’s adductor (Figs. 2.3g-i).  Interestingly, Hif-2 decreased, 
suggesting an alternative role for this alpha subunit.  These data suggest that 
ischemia promotes alternative splicing of VEGF favoring the soluble isoforms, 
whereas shear-induced collateral remodeling is associated with expression of the 
matrix-bound isoforms. 
Compared to wild-type mice, VEGFhi/+ exhibited less (Fig. 2.4a) whereas 
VEGFlo/+ experienced greater (Fig. 2.4b) ischemic appearance scores after 
femoral artery ligation.  Likewise, VEGFhi/+ mice exhibited less reduction in 
perfusion immediately after ligation and better recovery thereafter (Figs. 
 29 
 
2.4c,e,f), whereas VEGFlo/+ experienced greater reduction and worse recovery 
(Figs. 2.4d,e,f).  The milder ischemia in VEGFhi/+ is consistent with their trend 
toward a smaller increase in VEGF120 in the calf, compared to wild-type (Fig. 
2.3b).  The slight reduction of VEGF120 in VEGFlo/+, compared to wild-type, and 
the decrease of VEGF164 (Fig. 2.3c) may reflect the reduced stability of VEGF 
transcripts in the VEGFlo/+ strain.131 
Since vascular smooth muscle tone is absent immediately after femoral 
artery ligation,150 leg perfusion measured at this time largely reflects anatomical 
differences in pre-existing collateral density and/or diameter, and to a lesser 
extent, capillary density.  Thereafter, recovery of perfusion is primarily 
determined by collateral remodeling, with a smaller contribution of angiogenesis.  
To distinguish VEGF’s potential effect on these determinants, we first examined 
capillary-to-muscle fiber ratio in gastrocnemius at baseline (Figs. 2.5a,b).  There 
was no difference between wild-type and VEGFhi/+ or VEGFlo/+ mice.  This 
suggests a difference in collateral number and/or diameter underlies the 
differences in perfusion immediately after ligation.  Capillary-to-fiber ratio 
increased at 21 days in VEGFhi/+.  Interestingly, baseline fiber size was greater in 
VEGFhi/+, consistent with VEGF’s role in skeletal muscle development (Suppl. 
Figs. 2.1c,g).106  Capillary-to-fiber ratio decreased at 21 days in VEGFlo/+ mice.  
While capillary number-per-tissue-area of VEGFlo/+ did not differ from wild-type, 
greater atrophy occurred (Suppl. Figs. 2.1d,h), resulting in reduced capillary-to-
muscle fiber ratio.  These differences in capillary density which are consistent 
with VEGF’s role in ischemic angiogenesis, could contribute to the differences in 
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recovery of hindlimb perfusion and ischemic scores (Fig. 2.4), although collateral 
remodeling is the primary determinant of recovery of hindlimb perfusion.  
Given the importance of collateral conductance following femoral artery 
ligation, we determined collateral diameter at baseline and 21 days after ligation.  
Lumen diameters in VEGFhi/+ mice were significantly smaller than wild-type at 
both time-points; however percent remodeling and adductor perfusion in VEGFhi/+ 
were not different (Fig. 2.5c, Suppl. Fig. 2.2f).  In contrast, baseline diameters in 
VEGFlo/+ mice did not differ from wild-type, however remodeling and adductor 
perfusion were significantly reduced (Fig. 2.5d, Suppl. Fig. 2.2g).  The baseline 
diameter data suggest (since baseline capillarity do not differ) that differences in 
collateral density may underlie the differences in perfusion immediately after 
ligation, ie, greater number of smaller diameter collaterals in VEGFhi/+, versus 
fewer in VEGFlo/+.  In addition, less remodeling in VEGFlo/+ mice suggests VEGF 
contributes to collateral remodeling. 
 
VEGF gene dosage determines the number of pre-existing collaterals. 
To determine if VEGF expression influences native collateral density, as 
suggested by the above findings, we performed X-ray arteriography immediately 
and 7 days after ligation (the latter to improve detection of smaller collaterals 
after onset of remodeling).  Analogous to Rentrop analysis, we counted vessels 
crossing a line drawn through the middle of the adductor collateral zone (Fig. 
2.6a); this method agrees with other methods of quantifying pre-existing 
collateral capacity in the hindlimb.23  An apparent VEGF gene dose-relationship 
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was detected, wherein VEGFhi/+ had more and VEGFlo/+ had fewer collaterals 
than wild-type mice (Fig. 2.6b). 
We next sought to determine if collaterals are present at birth and if VEGF 
expression correlates with newborn and adult density in another tissue besides 
skeletal muscle.  We recently reported that differences in collateral density 
among mouse strains exist across multiple tissues.23  This includes collaterals of 
the cerebral cortical circulation, which are confined to the pial (leptomeningeal) 
membrane and thus readily quantified.23  We therefore counted pial collaterals in 
VEGFhi/+, VEGFlo/+ and wild-type mice using a polyurethane casting agent (Fig 
2.6c).146  Interestingly, collaterals were present at birth (P1; Fig 2.6d).  As in the 
hindlimb (Figs 2.6b) an apparent VEGF gene dose-relationship was detected at 
P1, P21 and 3-months of age, with VEGFhi/+ mice having more and VEGFlo/+ 
having fewer collaterals (Figs. 2.6c,d).  Wild-type and VEGFhi/+ mice were born 
with the same number of collaterals while VEGFlo/+ were born with fewer, 
suggesting VEGF levels specify the density of nascent collaterals formed during 
embryogenesis.  In VEGFhi/+, pial collateral number remained constant 
throughout post-natal development.  In contrast, wild-type mice experienced a 
decline in collateral density by P21 that remained unchanged in adults.  VEGF lo/+ 
mice also lost collaterals with age.  These data suggest that collaterals form 
during the perinatal period, that VEGF is important in their formation, and that 
VEGF is a determinant of their post-natal maturation and establishment of the 





Our findings suggest that VEGFR-1 positively regulates arteriogenesis 
through mobilization and recruitment of leukocytes to the peri-collateral region.  
We also provide the first examination of when the collateral circulation becomes 
established, finding that pial collaterals achieve their adult density by the third 
postnatal week.  In addition, we identify the first gene, VEGF-A, whose 
expression impacts native collateral formation.  
The signaling pathways that direct remodeling of pre-existing collaterals in 
ischemia remain unclear.25  Few studies have addressed whether endogenous 
VEGF mediates collateral growth.  Supportive evidence exists in hindlimb134, 135 
and heart136 ligation models, where systemic administration of sFlt1/sFlk1 
adenovirus134, VEGF receptor inhibitor135 or neutralizing antibody136 impaired 
recovery of perfusion and angiographic collateral growth.  Our findings that 
VEGFR-1+/- mice show reduced recovery of plantar and adductor perfusion, 
greater ischemia, reduced peri-collateral leukocyte accumulation and reduced 
collateral enlargement —but normal angiogenesis— suggest that VEGF acting 
through VEGFR-1 mediates collateral remodeling.  This is in contrast to VEGFR-
1’s role as a VEGF inhibitor during development.137, 142  It is difficult to measure 
VEGFR-1 signaling due to its weak kinase activity.113  However, studies using the 
VEGFR-1 specific agonists, PlGF and VEGF-B, and kinase-dead mutants find 
that VEGFR-1 possesses signaling functions in the adult.137, 142  Our data add 
collateral growth to these functions.  They also agree with evidence that mice 
lacking PlGF have impaired recovery from hindlimb ischemia.80  In addition, our 
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findings of fewer leukocytes circulating and residing around remodeling 
collaterals, which suggest reduced leukocyte mobilization and transmigration, are 
consistent with their known role in arteriogenesis.80   These results are congruent 
with VEGFR-1’s expression on leukocytes142 and its proposed role in the bone 
marrow niche151, in homing152 and in mediation of chemotaxis.110  No deficits 
were evident in VEGFR-2+/- mice.  However given VEGFR-2’s strong kinase 
activity, a single allele may specify sufficient receptor density to mediate VEGFR-
2-dependent ischemic angiogenesis as well as any potential contribution of this 
receptor to arteriogenesis.  This could explain why angiogenesis in the ischemic 
gastrocnemius was not impaired in VEGFR-2+/-.  Conditional deletion of VEGFR-
2 will be required to confirm that VEGFR-2 does not participate in collateral 
growth. 
Collaterals are small in diameter and few in number.  In addition, current 
antibodies cannot distinguish among VEGF isoforms and have limited resolution 
to detect secreted ligand.  Thus, it is not known if VEGF isoforms are increased 
around remodeling collaterals to contribute, directly or indirectly along with other 
cytokines, to arteriogenesis.  Deindl and colleagues117 did not detect increased 
VEGF in rabbit collaterals or in whole quadriceps muscle 3 days after femoral 
ligation.  In contrast, we found that mRNAs for high-molecular weight isoforms of 
VEGF increased in the adductor collateral zone of wild-type mice 36 hours after 
ligation.  Since transcript levels of VEGF agree with protein expression153 this 
discrepancy may be due to differences in duration of ligation, tissue analyzed or 
species studied.  We assayed a 5mm wide section in the middle of the adductor 
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that contains hindlimb collaterals, including those in the gracilis muscles that we 
measured histologically.  In contrast to the adductor, only VEGF120 was 
upregulated in the gastrocnemius.  This differential expression in tissues where 
collaterals are remodeling versus where capillaries are sprouting, is consistent 
with the different physical properties and functions of VEGF isoforms.  In the calf, 
free diffusion of VEGF120 would promote a wide area of angiogenesis.  In 
addition, VEGF120 released into the circulation from ischemic tissue aids 
mobilization of leukocytes from bone marrow.151  In contrast, collateral growth in 
the thigh is presumed to require temporal and spatial release of proteases, 
cytokines, and growth factors.  Elaboration of the heparin-binding VEGF164 and 
VEGF188 isoforms around collaterals may establish VEGF gradients that 
stimulate diapedesis and proliferation of leukocytes, proliferation of endothelial 
cells, and migration of smooth muscle cells.  It will be important in future studies 
to determine the cell source(s) and stimulus for VEGF release.  Endothelium, 
smooth muscle, peri-collateral leukocytes and fibroblasts, and skeletal muscle 
are all potential sources of VEGF. 
Deindl and colleagues117 also did not detect increased Hif-1 in the 
adductor, although differences in species, time after ligation and tissue sampled 
could be important.  In contrast, we found a ~two-fold increase in Hif-1 mRNA 
(and no increase in Hif-1) in the adductor collateral zone.  Since Hif-1 levels 
are regulated by tissue oxygen over a broad range,154 it is possible that oxygen 
declines sufficiently, though not to ischemic levels, to increase transcription and 
stabilization of Hif-1 transcripts.  In addition, it is possible that other factors in 
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the extracellular milieu surrounding remodeling collaterals that regulate Hif-1, 
such as reactive oxygen species, nitric oxide and certain growth factors155, may 
contribute to the increase in Hif-1. 
Consistent with deficient recovery of flow after femoral ligation in VEGFR-
1+/-mice, a direct relationship was evident between VEGF gene dosage and 
recovery among VEGFlo/+, wild-type and VEGFhi/+ mice.  Compared to wild-type 
mice, VEGFlo/+ had worse ischemic appearance scores and blunted recovery of 
plantar perfusion that were similar to VEGFR-1+/-.  In contrast, VEGFhi/+ mice 
showed enhanced recovery of perfusion and little ischemia.  In addition, VEGF lo/+ 
mice exhibited attenuated adductor perfusion and impaired collateral remodeling 
like that seen in the VEGFR-1+/- mice.  On the other hand, collateral remodeling 
and adductor perfusion were not enhanced in VEGFhi/+.  Although this appears 
discordant, several considerations are important.  Immediately after ligation, 
perfusion decreased more in VEGFlo/+ and less in VEGFhi/+ mice.  The increase in 
shear stress in collaterals immediately after ligation favors inhibition of collateral 
smooth muscle tone.  Moreover, ischemia and low pressure cause myogenic and 
metabolic inhibition of tone in the vasculature below the point of ligation.150  
These considerations suggest that the differences in perfusion immediately after 
ligation arise from anatomical differences in pre-existing collateral number, 
collateral lumen size and/or capillary density.  Capillary density was not different 
among VEGFhi/+, VEGFlo/+ and controls, and collateral lumen diameter was 
comparable in the latter two groups while being smaller in VEGFhi/+ mice.  
Collectively, these data suggest that density of native collaterals varies directly 
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with level of VEGF expression.  In VEGFhi/+ mice, a greater number of collaterals 
in parallel favors lower flow in individual collaterals and thus smaller baseline 
diameters, which is what we observed.  Shear stress is the proximate stimulus of 
arteriogenesis.8, 25  A greater number of collaterals favors less increase in shear 
in individual collaterals, which is consistent with our finding that remodeling was 
not greater in VEGFhi/+ mice than in wild-type despite increased VEGF 
expression.  In VEGFlo/+ mice with fewer collaterals, the expected higher shear 
forces may not be able to overcome the deficit in VEGF expression.  This could 
explain the reduced collateral remodeling and impaired perfusion that we 
observed. 
We found that VEGF expression determines collateral density in a second 
tissue —the pial circulation— where like skeletal muscle, density was greater in 
VEGFhi/+ and lower in VEGFlo/+ mice.  An additional intriguing finding was that 
VEGFlo/+ mice were born with fewer pial collaterals compared to wild-type and 
VEGFhi/+ mice.  These data suggest that VEGF levels contribute to collateral 
formation in the embryo.  We previously hypothesized that collaterals form during 
embryonic arterial tree formation and that reduced VEGF expression results in 
reduced collateral formation.23  VEGF has been implicated in branching 
morphogenesis.111, 156-158  Our data support the postulate that collateral density 
and vascular branching are intimately related.  In addition, collateral density was 
reduced by post-natal day 21 in wild-type and VEGFlo/+ mice, while density was 
maintained in VEGFhi/+ mice.  This is consistent with VEGF’s role in stabilizing 
nascent blood vessels.137, 138, 142 
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We reported that native collateral density and VEGF expression differ 
strongly in two mouse strains.23  Inducible VEGF expression and collateral 
density in hindlimb, cerebral cortex and intestine were high in C57BL/6 mice and 
low in BALB/c.  This association led us to hypothesize that VEGF is a 
determinant of native collateral formation.  Our present studies using mice with a 
single targeted genetic difference, ie altered VEGF expression,130, 131, 145 provide 
strong support for this hypothesis.  Furthermore, they suggest that genetic 
polymorphisms and environmental factors that reduce VEGF expression during 
embryonic or perinatal periods could reduce collateral formation, resulting in 
increased severity of stroke, myocardial infarction and peripheral artery disease.  
How VEGF affects collateral formation and stabilization are intriguing questions 
for future study.   While no studies have described when and how collaterals 
form, our data suggests that collaterals form prior to birth and mature within a 
narrow three-week period in the mouse. 
While these findings indicate VEGF specifies collateral density in normal 
tissue, other molecules in the VEGF signaling pathway may also contribute to 
collateral density.  Resar and coworkers recently identified a HIF-1 
polymorphism in exon 12 that associated with the presence of coronary 
collaterals in patients.159  The C-to-T polymorphism results in a P582S amino-
acid substitution that confers increased HIF-1 activity.  However, patients with the 
T allele did not have visible collaterals, which is at variance with our findings.  
Among mechanisms proposed by the authors to explain the apparent 
discrepancy between higher HIF-1 activity and lack of visible collaterals,159  we 
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propose an additional hypothesis.  Because clinical angiography can only detect 
large vessels, individual collaterals in a person with a small native density would 
be more likely to experience larger increases in shear and thus to enlarge to 
detectable diameters during progression of coronary artery disease.  In contrast, 
collaterals in a person with a high native density would be expected to 
experience smaller increases in shear, resulting in less outward remodeling 
during disease progression and absence of detection by angiography.   
In addition to upstream activators of VEGF, downstream effectors may 
also influence native collateral density.  Endothelial nitric oxide synthase (eNOS) 
is an important signaling molecule induced by VEGF that contributes significantly 
to arteriogenesis.160  In a recent report, Mees and colleagues compared 
arteriogenesis in mice over-expressing eNOS (eNOS-Tg) versus mice lacking 
functional eNOS (eNOS-/-).160, 161  Of note, laser Doppler perfusion immediately 
after ligation decreased more in eNOS-/ - mice and less in eNOS-Tg mice, which 
we suggest may indicate a smaller versus larger native collateral density, 
respectively.  If correct, these results which parallel our present data would 
further support an important role for VEGF in establishing the density of native 
collaterals in tissues. 
In conclusion, our results suggest that VEGFR-1 mediates collateral 
growth in ischemic disease by mobilizing leukocytes and recruiting them to the 
peri-collateral space.  In addition we show that collaterals form prior to birth and 
stabilize at their adult density by the third postnatal week in mice.  Lastly, we 
identify VEGF as the first molecule specifying pre-existing collateral density in 
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normal tissue.  We propose a model whereby collaterals form in a VEGF-
dependent manner during embryogenesis.  Further, these nascent collaterals 
require adequate VEGF during a critical period after birth to stabilize and mature 
sufficiently to achieve their full adult density.  Further studies will be required to 
define when and how VEGF contributes to collateral formation, as well as the 
downstream effectors that stabilize and maintain collaterals in the adult.  It is 
known that coronary collateral flow in healthy patients varies over a wide 
range.162  Moreover, several VEGF polymorphisms linked to altered expression 
have been described.163  Thus, it will be important to examine whether 
polymorphisms affecting the expression of VEGF and other genes are associated 
with altered collateral density in humans.  An understanding of the pathways that 
specify collateral formation in normal tissues may lead to therapies to induce 
formation of new collaterals in adults with ischemic disease.  
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Figure 2.1:  Impaired recovery of perfusion in VEGFR-1+/- mice after 
femoral artery ligation.  (a,b) VEGFR-1+/- mice have greater hindlimb ischemic 
appearance score.  Scale: 0=normal, 1=cyanosis or loss of nail(s), 2=partial or 
complete atrophy of digit(s), 3=partial atrophy of fore-foot; n=6-20 per data-point.  
(c)  Laser Doppler perfusion images of plantar foot with region of interest (ROI).  
(d,e)  Quantification of plantar perfusion measured over ROI.  Data are 
mean±SEM for this and other figures.  Two-way ANOVA followed by Dunn-






Figure 2.2: Reduced collateral remodeling (lumen expansion) and 
leukocyte recruitment in VEGFR-1+/- mice.  (a) Lectin-stained capillaries in 
gastrocnemius muscle.  (d,g) Capillary number-to-muscle fiber number ratios at 
baseline (before) and 21 days after femoral ligation.  (b)  Cyano-Massons-
elastin-staining of collateral in gracilis muscle.  (e,h) Collateral lumen diameter at 
baseline and 21 days after ligation.  Numbers inside bars here and elsewhere are 
percent increase from baseline.  (c,f,i) CD45+ leukocytes in a 1-diameter area 
around anterior gracilis collaterals.  Paired t-Test vs. baseline; Un-paired t-Test 






Figure 2.3: Quantitative RT-PCR of VEGF isoforms (a-f) and HIF subunits 
(g-i) in calf (a-c) and adductor muscle (d-i) of wild-type (a,d,g), VEGFhi/+ (b,e,h), 
and VEGFlo/+ (c,f,i) mice.  Data for muscle taken from the ligated leg are relative 
to muscle from the non-ligated leg and normalized to 18S rRNA.  Non-parametric 





Figure 2.4: VEGFhi/+ mice have better and VEGFlo/+ worse recovery after 
femoral ligation.  (a,b) Lower ischemic appearance score in VEGFhi/+ and more 
ischemia in VEGFlo/+ (see Fig. 2.1 for scale); n=6-20 per data-point.  (c,d,e) 
Quantification of perfusion measured over plantar foot ROI shows less reduction 
in perfusion immediately after ligation (―Post-Op‖) and better recovery in 
VEGFhi/+, and opposite effects in VEGFlo/+.    (f) Representative Doppler images 
of Pre- and Post-Op time points.  ANOVA followed by Dunn-Bonferonni corrected 





Figure 2.5: Collateral remodeling and angiogenesis are attenuated in 
VEGFlo/+ mice.  Capillary number-to-muscle fiber number ratios (a,b) and 
collateral lumen diameters (c,d) before and 21 days after ligation.  Paired t-Test 
vs. Baseline; Unpaired t-test vs. wild-type; #p<0.05 vs. percentage change from 





Figure 2.6: Collateral density in skeletal muscle and pial circulations 
correlates with VEGF gene dosage.  (a)  Post-mortem X-ray arteriogram of thigh.  
Vessels were counted (data given in (b)) that crossed a line drawn from the mid-
point between the femoral ligations through the thigh collateral zone before and 7 
days after ligation.  (c) Post-mortem polyurethane arteriograph of pial circulation.  
Collaterals were counted (data given in (d)) that interconnected the middle and 
anterior cerebral artery trees at post-natal day-1, day-21 and 12 weeks.  
Brackets, 1-way ANOVA followed by Dunn-Bonferonni corrected t-Test; *p<0.05 






Supplemental Table 1: Whole blood leukocyte counts (103/l) are reduced 
in VEGFR-1+/- but not VEGFR-2+/- mice. 
 WBC LYMF GRAN MONO 
Wild-type 4.44 ± 0.27 2.92 ± 0.30 1.08 ± 0.08 0.44 ± 0.02 
VEGFR-1+/- 3.50 ± 0.19 2.18 ± 0.19 0.96 ± 0.04 0.36 ± 0.02 
p value 0.01 0.04 0.11 0.02 
 
Wild-type 3.84 ± 1.13 2.52 ± 1.02 0.86 ± 0.14 0.46 ± 0.08 
VEGFR-2+/- 4.32 ± 0.99 2.72 ± 0.78 1.14 ± 0.26 0.46 ± 0.07 
p value 0.49 0.39 0.15 0.45 
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Supplemental Figure 2.1: Capillary area density (a-d) and muscle fiber 
area (e-h) for VEGFR-1+/- (a,e), VEGFR-2+/- (b,f), VEGFhi/+ (c,g), and VEGFlo/+ 
(d,h) mice before (open bars) and 21 days after femoral ligation (black bars).  
Capillary area density increased in wild-type mice, with a similar trend in VEGFR-
1+/- mice (a).  Muscle fiber area declined similarly in wild-type and VEGFR+/- mice 
(e).  Together, the data suggest that VEGFR-1 haplo-insufficiency does not affect 
angiogenesis or muscle atrophy.  Capillary area density tended to increase more 
(b) and muscle fiber area tended to decrease more (f) in VEGFR-2+/- mice.  The 
higher capillary area density and smaller muscle fiber area resulted in an 
increase in capillary-to-muscle fiber number ratio (Fig. 2f), which suggests that 
heterozygosity does not impair angiogenesis.  Capillary area density increases 
slightly less in VEGFhi/+, consistent with a less ischemia in the hindlimb (c).  
Interestingly, VEGFhi/+ muscle fiber area was greater at baseline and at 21 days 
(g).  The difference in muscle fiber area may indicate altered skeletal muscle 
physiology from chronic VEGF overexpression.  Capillary area density was not 
different in VEGFlo/+ mice, which is incongruent with increased ischemia (d).  
However, there is greater atrophy of skeletal muscle, which is consistent with 
increased ischemia in VEGFlo/+ mice (h).  Together, these data explain the slight 





Supplemental Figure 2.2: VEGFR-1+/- and VEGFlo/+ mice have attenuated, 
and VEGFR-2+/- and VEGFhi/+ mice have normal perfusion over the adductor 
collateral zone.  (a-c) Representative laser Doppler images of the ventral 
adductor with ROI outlined.  Collateral perfusion is blunted in VEGFR-1+/- 
suggesting a positive role for VEGFR-1 in mediating arteriogenesis (d).  Impaired 
collateral perfusion is likely due to a decrease in collateral remodeling (Fig. 2e) 
as a result of a decrease in leukocyte recruitment (Fig. 2f) and leukocyte 
mobilization (Suppl. Table 1).  Adductor perfusion is unchanged in VEGFR-2+/- 
mice, suggesting that VEGFR-2 is not required for collateral remodeling or, 
despite heterozygosity, receptor density and/or signaling is sufficient to mediate 
normal arteriogenesis (e).  In VEGFhi/+ mice, collateral perfusion is not different 
from wild-type (f) while adductor perfusion is decreased in VEGFlo/+ (g).    
Inhibition of adductor perfusion in VEGFlo/+ is consistent with attenuation of 
perfusion in VEGFR-1+/- and suggests a model whereby sufficient VEGF levels 
are required to adequately recruit VEGFR-1-containing leukocytes to the growing 
collateral.  However, collateral perfusion from VEGFhi/+ would seem to contradict 
that model.  This could reflect that VEGF expression exceeding wild-type levels 
may not be able to further augment collateral remodeling.  Consistent with this, 
no further augmentation of collateral lumen diameter was observed in VEGFhi/+ 
mice (Fig. 5c).  Alternatively, the greater number of native collaterals in VEGFhi/+ 
mice (Fig. 6) favors reduced flow and shear in any individual collateral.  A 
decrease in the shear stimulus, combined with an increase in VEGF production, 





Supplemental Figure 2.3: Quantitative RT-PCR of non-ischemic calf 
skeletal muscle confirms genotype of VEGFhi/+ and VEGFlo/+ mice (a).  VEGF 
expression in normal skeletal muscle has not been previously reported in these 
adult mouse models.  VEGFhi/+ mice have 2-fold greater levels of the major 
VEGF isoforms while there is a 25-75% decrease in them in VEGFlo/+ mice.  Non-
ischemic adductor HIF subunit expression is similar in all genotypes 
demonstrating no VEGF-dependent alteration in HIF expression.  Data show 
expression in non-ischemic muscle of VEGFhi/+ or VEGFlo/+ relative to non-
ischemic wild-type muscle.  Data are normalized to 18S rRNA.  Non-parametric t-





 CHAPTER 3 
Paracrine VEGF Signaling is Essential for Arteriogenesis 
 
ABSTRACT 
Arteriogenesis (collateral artery growth in ischemia) is a critical vascular 
adaptation to ischemic vascular disease.  It is a complex process that requires 
the recruitment of leukocytes and elaboration of growth factors, cytokines, and 
proteases.  The role of VEGF in arteriogenesis is controversial.  Studies 
administering exogenous VEGF have shown both positive and negative results 
for improved arteriogenesis and perfusion recovery.  Alternatively, systemic 
inhibition of VEGF has demonstrated a positive role for endogenous VEGF in 
arteriogenesis.  However, both of these approaches can indirectly lead to 
augmentation or inhibition of arteriogenesis through secondary actions on 
hemodynamics and leukocyte mobilization. Currently, no studies have 
conclusively identified a direct role for VEGF in arteriogenesis.  Therefore, we 
examined the role of local VEGF secretion and signaling in mediating collateral 
growth.  We found selective VEGF expression in cells surrounding remodeling 
collaterals, but not quiescent collaterals or similarly sized arterioles.  Deletion of 
VEGF in the adductor via electroporation of Cre recombinase in VEGFloxP/loxP 
mice led to increased ischemic appearance and limb use impairment scores, and 
attenuated recovery of plantar perfusion.  These results suggest that tissue 
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resident cells are a source of arteriogenic VEGF.  Electroporation of FltIgG 
(VEGF trap) similarly increased ischemic appearance and limb use scores.  
While recovery of plantar perfusion was unaffected, adductor perfusion was 
attenuated in FltIgG animals, suggesting impaired collateral remodeling.  




The molecular mediators of arteriogenesis, ie, collateral artery growth in 
ischemia, remain incompletely defined.  Studies have found that exogenous 
administration of certain growth factors and cytokines, including VEGF can both 
augment61-66 and impair124, 125 collateral growth.   In the case of VEGF, 
disagreements could arise from differences in methods of delivery which have 
included plasmids, viruses, and protein, and variation in concentrations.  It is 
clear from studies of therapeutic angiogenesis that a narrow window of VEGF 
expression is required, such that too much or too little, renders the molecule 
ineffective.130-133  Not only is the concentration of VEGF important, but the 
cellular and tissue distribution of the isoforms can alter its function.138 
Systemic administration of exogenous VEGF is problematic in that it is a 
pleiotropic molecule with both direct and indirect actions on each of the cell types 
involved in arteriogenesis.  VEGF mobilizes leukocytes from the bone marrow, 
and increases their transmigration, which is required for arteriogenesis.36-39, 59, 110, 
114  VEGF, through activation of eNOS, is a potent vasodilator, which may 
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increase flow and shear in the collateral circulation and thus indirectly augment 
collateral remodeling.100  Similarly, VEGF-induced angiogenesis in ischemic 
tissue favors reduction in resistance downstream of the occlusion and increased 
flow and shear in the collateral circulation.   
The above difficulties make clear that strategies are needed to manipulate 
endogenous VEGF locally in the collateral region to understand the biological 
function of VEGF in arteriogenesis.  Reports have shown that systemic inhibition 
of VEGF can attenuate collateral remodeling and perfusion recovery.134-136  
However, similar to systemically increasing VEGF expression, systemic blockade 
can indirectly cause inhibition of arteriogenesis through similar secondary effects.   
In the present study, we tested the hypothesis that local endogenous VEGF is 
necessary for arteriogenesis and recovery  of perfusion in occlusive vascular 
disease.  We used in vivo electroporation to deliver plasmids encoding Cre-
recombinase into the adductor of VEGFloxP/loxP mice, the site of the main 
collateral circulation to hindlimb.  We also delivered FltIgG, a VEGF-trap, into the 
adductor of C57BL/6 mice and assessed perfusion recovery and arteriogenesis. 
 
MATERIALS AND METHODS 
Immunofluorescence.  7 days after ligation, VEGFhi/+ mice were 
pressure-perfused transcardially (100mmHg) with phosphate-buffered saline 
(PBS, pH7.4) containing 20mmol/L adenosine, 10-4mol/L papaverine and 10U/ml 
heparin, followed by pressure-perfused fixation with 4% paraformaldehyde in 
100mmol/L sodium phosphate (PFA; pH7.4) for 15min  The adductor was 
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excised in a 5mm block extending ~1mm medial of the ―mid-zone‖ of the gracilis 
collaterals that interconnect the lateral caudal femoral artery and saphenous 
artery trees, to the lateral portion of the thigh.  Blocks were paraffin-embedded 
and sectioned at 5µm.  -galactosidase was detected with rabbit anti--
galactosidase antibody (ab616, Abcam, 1:100) followed by Cy5-conjugated 
donkey anti-rabbit antibody (Jackson Immuno Research, 1:500).  Leukocytes 
were detected with rat anti-CD45 antibody (clone 30-F11, BD Pharmingen, 
1:100) followed by FITC-conjugated donkey anti-rat antibody (Jackson Immuno 
Research, 1:500). 
Plasmid construction.  The parental plasmid used in this study, pIRES 
(Clontech) contains a CMV promoter driving the transcription of the genes of 
interest.  pIRES-LacZ: LacZ was PCR amplified (Phusion high-fidelity 
polymerase, NEB) from pBI-G (Clontech) with primers LacZ F-1 and LacZ R-1 
(see Table 3-1 for list of oligos used in this study) and ligated into the XbaI / NotI 
site of pIRES.  pCre-IRES-LacZ:  Cre was amplified from pCMV5-Cre-NF (gift 
from R Sealock) with Cre F-1 and Cre-R1 and ligated into the NheI / EcoRI site of 
pIRES-LacZ. 
pIRES3:  pIRES was subjected to 3 rounds of mutagenesis.  Round 1: 
pIRES was amplified with IRES F-1, IRES R-1, mutIRES2-F, and mutIRES2-R.  
The PCR fragment was digested with NheI and XbaI and ligated into the 
corresponding sites of pIRES to yield pIRES2.  Round 2:  pIRES2 was amplified 
with IRES F-2, IRES R-1, mutIRES3-F1, and mutIRES3-R1.  PCR product was 
digested with PflMI and XbaI and ligated into the corresponding sites of pIRES2 
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to yield pIRES3x.  Round 3:  pIRES3x was amplified with IRES F-3, IRES R-2, 
mutIRES3-F2, and mutIRES3-R2.  The PCR product was digested with NdeI and 
XhoI and ligated into the corresponding sites of pIRES3x to yield pIRES3. 
pLuc-IRES3:  Luciferase was amplified from pBI-GL (Clontech) with Luc-
F1 and Luc-R1, digested with XbaI and SalI and ligated into NheI / XhoI of 
pIRES3.  pLuc-IRES3-LacZ:  LacZ was amplified from pBI-G with LacZ F-2 and 
LacZ R-2, digested with XbaI and SalI and ligated into XbaI / SalI of pLuc-IRES3.  
pLuc-IRES3-FltIgG:  FltIgG was amplified from pAdEasy-FltIgG (kindly provided 
by N Ferrara) with FltIgG F-1 and FltIgG R-1, digested with XbaI and SalI and 
ligated in XbaI / SalI of pLuc-IRES3. 
In vivo electroporation.  Mice were anesthetized with 1.125% 
isoflurane/O2.  Dorsal and ventral hindlimbs were depilated.  Using a 32g needle 
collared to confine penetration to ~2 mm and micro-manipulator control, 50l of 
0.8 U/l hyaluronidase (Sigma) was injected into 3 sites in the adductor and 3 
sites in the abductor, adjacent to the body wall in both right and left legs (Fig. 3.2 
a).  2 hours after hyaluronidase treatment, 50l plasmid, 1 g/l, was injected 
into the same sites in the adductor and abductor muscle groups of both legs.  
Electrode paste was applied to the thigh and 8 pulses of 1ms duration at 125 
V/cm were applied to the thigh with 1cm caliper electrodes (BTX). 
In a separate study, Ibuprofen (0.2 mg/ml, IBU) was added to the drinking 
water 7 days before electroporation and for the duration of the study, to assess 
the ―inflammatory‖ hyperemic response to electroporation. 
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Unilateral hindlimb ischemia.  3 and/or 13 days after electroporation, 
mice received unilateral femoral artery ligation.  12 to 14 week-old mice were 
used in all studies.  VEGFloxP/loxP mice were kindly provided by N Ferrara.164  
C57BL/6 mice were purchased from Jackson Laboratories.  VEGFhi/+ mice were 
a gift of A Nagy.145  Animals were randomized and procedures and analyses 
were conducted blindly.  Femoral artery ligation was performed as described.23, 34  
Briefly, mice were anesthetized with 1.25% isoflurane/O2 and the hindlimbs 
depilated.  Temperature was maintained at 37.0±0.5ºC.  The right femoral artery 
was exposed through a 2mm incision and ligated with two 7-0 ligatures placed 
distal to the origin of the lateral caudal femoral and superficial epigastric arteries 
(the latter was also ligated) and proximal to the genu artery.  The artery was 
transected between the sutures and separated by 1-2 mm.  The wound was 
irrigated with sterile saline and closed, and cefazolin (50mg/kg, im), furazolidone 
(topical) and pentazocine (10mg/kg, im) were administered.  Procedures were 
approved by the University of North Carolina Institutional Animal Care and Use 
Committee.    
Laser Doppler perfusion imaging.  As detailed previously,23, 34 under 
1.125% isoflurane/O2 anesthesia and 37±0.5ºC, non-invasive perfusion imaging 
of the adductor thigh region and plantar foot of both limbs was performed before, 
immediately after, and at 3, 7, 14, and 21 days after femoral ligation.  Regions of 
interest (ROI) were drawn to anatomical landmarks.   
Assessment of ischemia.  An ―appearance score‖ after ligation was 
obtained, where 0=normal, 1=cyanosis or loss of nail(s), 2=partial or complete 
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atrophy of digit(s), 3=partial atrophy of fore-foot.23  A ―use score‖ was similarly 
obtained, where 0=normal, 1=no toe flexion or toe spreading, 2=ambulation with 
the foot but no plantar flexion, 3=mouse drags foot.23 
Leukocyte counts.  Three days after femoral ligation, blood was collected 
into EDTA tubes (Sarstedt) under anesthesia by sub-mandibular puncture 
(Medipoint).  Leukocyte counts (CBC) were performed with a Heska’s Animal 
Blood Counter. 
Whole mount X-gal staining.  7 or 21 days after electroporation, the 
abdominal aorta was cannulated and animals were pressure-perfused 
(100mmHg) with phosphate-buffered saline (PBS, pH7.4) containing 20mmol/L 
adenosine, 10-4mol/L papaverine and 10U/ml heparin, followed by pressure-
perfused fixation with 4% paraformaldehyde in 100mmol/L sodium phosphate 
(PFA; pH7.4) for 15min.  X-gal wash buffer (PBS, 2mM MgCl2) was perfused 
followed by X-gal staining solution (X-gal wash buffer, 5mM potassium 
ferricyanide, 5mM potassium ferrocyanide, X-gal at 1mg/ml).  Hindlimbs were 
removed and incubated in X-gal staining solution at 37ºC overnight. 
Xenogen luciferase imaging.  Animals were injected IP with 30mg/kg 
luciferin (Caliper Life Science) and allowed to ambulate for 5 minutes.  Mice were 
then anesthetized with 2% isoflurane/O2 until recumbent and positioned in the 
light tight chamber of the IVIS100 under 1.5% isoflurane/O2 .  Photons were 
collected and integrated for 1 second intervals at 10 and 15 minutes following 
injection of luciferin for the ventral surface and 20 and 25 minutes for the dorsal 
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surface.  Living Image software was used to automatically generate ROI’s above 
10% threshold.  Data are reported as photons/sec. 
Statistics.  All data are reported as means ± SEM.  Significance (P<0.05) 
was determined by two-way ANOVA followed by Dunn-Bonferonni Corrected t-
tests.  One-way ANOVA was used for comparisons of plasmid effect on CBC 
over time, followed by paired or un-paired t-tests. 
 
RESULTS 
VEGF is localized to remodeling collaterals and not to other arterioles. 
While it is known that in vitro, cells surrounding the collateral and cells of 
the collateral wall are capable of expressing VEGF, it is not clear whether or not 
these cells express VEGF in the context of arteriogenesis.  To assess this, we 
examined -galactosidase (-gal) expression in VEGFhi/+ mice.  VEGFhi/+ mice 
have a targeted mutation that permits -gal to be expressed, in a bi-cistronic 
manner, with VEGF.145  -gal is thus a surrogate for VEGF expression.  
Immunofluorescence of -gal in gracilis collaterals reveals increased staining in 
skeletal muscle fibers surround the remodeling collateral (Fig. 3.1a) whereas 
very little staining is seen in non-ligated collaterals (Fig. 3.1d).  To determine if 
this staining was collateral specific, we analyzed -gal immunoreactivity in other 
arterioles in the adductor (identified as 25-50 m diameter vessels with no 
associated vein or nerve).  An arteriole found in the adductor magnus muscle 
group showed reduced staining similar to that seen in the non-ligated collateral 
(Fig. 3.1g).  In addition to skeletal muscle expression of -gal, we see co-
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localization of -gal with CD45 (Fig. 3.1b), a marker for leukocytes, suggesting 
that recruited leukocytes also express VEGF. 
 
In vivo electroporation produces localized and sustained gene expression. 
After optimization of plasmid concentrations and electrical parameters 
(data not shown), we wanted to examine the extent and duration of plasmid 
expression in electroporated thighs.  First, we injected and electroporated pIRES-
LacZ.  Despite injecting in the medial portion of the thigh (Fig. 3.2a), we show 
high level of X-gal staining throughout the length of the muscle fiber.  This 
expression turns on relatively early (day 7) and lasts for at least three weeks 
(Fig. 3.2b,c).  In addition, plasmid electroporation results in tissue-restricted 
expression in that we see no evidence of LacZ expression in the gastrocnemius 
muscle (Fig. 3.2d). 
A disadvantage of using LacZ as a reporter of plasmid expression, is that 
the extent of tissue transfection can only be assessed by sacrificing the animal.  
We therefore, constructed a plasmid containing a luciferase gene to allow non-
invasive imaging of the same animal over an extended time-course, pLuc-IRES3-
LacZ.  Consistent with data from pIRES-LacZ, in vivo luciferase imaging of pLuc-
IRES3-LacZ showed restricted expression in the thigh and long duration of 
expression, up to 21 days post-ligation (24 days post-electroporation) (Fig. 3.5a-
e).  Quantitation of luciferase expression is easily done and shows a high level of 
sustained expression (Fig. 3.5e).  A disadvantage of luciferase imaging is that 




Cre-mediated VEGF deletion in the thigh results in impaired perfusion recovery. 
We wanted to test the hypothesis that local VEGF expression is necessary 
for collateral growth.  Three days after plasmid electroporation with pIRES-LacZ 
(control) or pCre-IRES-LacZ, VEGFloxP/loxP mice underwent unilateral femoral 
artery ligation.  Consistent with this hypothesis, ischemic appearance score 
tended to be worse and limb use was more impaired in mice receiving Cre 
expressing plasmid (Fig. 3.3a,b).  In addition, plantar perfusion recovery tended 
to be reduced in mice receiving Cre plasmid in the adductor  (Fig. 3.3c,e).  There 
was no difference in adductor perfusion (Fig. 3.3d,f) between the two groups. 
The tendency for adductor perfusion to be greater in the group receiving 
Cre plasmid (Fig. 3.3f) was unexpected, and we were concerned that plasmid 
electroporation, alone, might be altering blood flow in the thigh.  Analysis of the 
raw perfusion values revealed a ―hyperemic‖ response in the control group that 
was resolved by 7 days post-ligation (10 days post-electroporation) (Fig. 3.4a,b).  
Interestingly, this response was attenuated in mice receiving Cre-plasmid (Fig. 
3.4b), suggesting an involvement of VEGF.  We then assessed whether this was 
an inflammatory mediated ―hyperemic‖ response.  We tested administration of 
ibuprofen (in drinking water) beginning 7 days prior to electroporation and 
throughout the experiment.  Ibuprofen administration did not attenuate the local 





Position of gene of interest in pIRES affects level of expression. 
In a recent report it was shown that gene expression in pIRES was 
dependent on the position, multiple cloning site (MCS) -A or –B (upstream and 
downstream of IRES respectively), and the sequence of the IRES.165  pIRES is 
an attenuated mutant designed to give equal expression at both MCS-A and 
MCS-B.  The wild-type IRES gives approximately 100 fold greater expression of 
the gene inserted into MCS-B than when inserted into MCS-A.  The relatively low 
expression of Cre-recombinase may explain our failure to reach significance in 
our experiments.  We therefore redesigned our plasmids by replacing the 
attenuated IRES sequence with the wild-type IRES sequence to generate 
pIRES3.  We then cloned our reporter gene in MCS-A and FltIgG into MCS-B to 
ensure a high level of expression. 
 
Adductor expression of FltIgG, a VEGF sequestering molecule, worsens 
ischemic appearance and limb use and impairs adductor perfusion. 
While local VEGF deletion defines a role for VEGF expression from 
resident cells (ie, collateral wall cells, tissue macrophages, skeletal muscle), it 
does not address the possibility that systemic VEGF sources (ie, from ischemic 
calf) can affect collateral growth.  To address this possibility we electroporated a 
plasmid encoding FltIgG, a VEGF-Trap, into the adductor and analyzed recovery 
from hindlimb ischemia. 
FltIgG is a chimeric molecule designed for increased stability and half-
life.164  It also contains residues that confer increased binding to extracellular 
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matrix.166  It is not a true antagonist, in that it does not bind to the receptor.  
Instead, it binds VEGF with high affinity thus preventing its binding and activation 
of VEGF receptors, acting as a molecular VEGF sponge. 
Expression of FltIgG in the adductor significantly increased the ischemic 
appearance scores and impaired limb use scores compared to LacZ control (Fig. 
3.6a,b).  Plantar perfusion was not different in the two groups consistent with the 
absence of VEGF inhibition in the circulation and in calf (Fig. 3.6c).  Adductor 
perfusion was significantly attenuated in FltIgG animals consistent with a role for 
VEGF inhibition in collateral remodeling and perfusion. 
 
Adductor FltIgG does not affect circulating white blood cell populations. 
The distribution of white blood cell types was not different between FltIgG 
and LacZ control groups (Fig 3.7).  This is consistent with the failure of FltIgG to 
escape from the adductor tissue and circulate systemically, inhibiting leukocytes 
mobilization.  The white blood cell count revealed a distinct pattern during the 
course of ligation.  Lymphocytes gradually decreased approximately 20% by day 
7 of ligation (day 10 post electroporation) (Fig. 3.7a).  Granulocytes showed an 
increase by day 7 of ligation, consistent with an acute inflammatory response 
(Fig. 3.7b).  Monocytes did not change for the first 2 weeks, but increased at 21 







Our findings reveal a positive role for paracrine VEGF signaling in 
arteriogenesis in the thigh.  We have shown that deletion of VEGF and 
expression of FltIgG in the thigh impairs perfusion recovery in the plantar foot 
and adductor, respectively.  In addition, we have successfully used in vivo 
electroporation to obtain long term, sustained, and tissue restricted expression of 
our gene of interest. 
The role for VEGF in arteriogenesis is still controversial with studies 
showing both impairment and augmentation of collateral growth and tissue 
recovery with systemic delivery. 61-75, 117, 124-127  This conflict is largely due to the 
complex biology of VEGF and its pleiotropic actions on multiple cell types 
involved in arteriogenesis.  The importance of endogenous VEGF has been 
demonstrated in studies blocking the actions of VEGF.134-136  However, the 
caveats of systemic VEGF manipulation remain.  
We have utilized in vivo electroporation as a tool to locally express 
inhibitors of VEGF only in the adductor, where collaterals are found.  This 
technique permits VEGF to function in other tissues, such as in the calf to 
mediated angiogenesis and in the circulation to mediate vasodilation and 
leukocyte mobilization.  For the first time, we have dissected a direct role for 
VEGF in arteriogenesis.  In the thigh, the predominant cell type that is 
transfected is skeletal muscle.167  Muscle is also potentially the largest source of 
secreted VEGF.  Therefore, deletion of VEGF from this tissue was our first goal.  
Using conditional VEGF mice, VEGFloxP/loxP,164 and plasmid expressing Cre-
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recombinase, we showed attenuation in plantar perfusion, which is consistent 
with impaired collateral remodeling.  In a parallel experiment, we electroporated a 
plasmid carrying the FltIgG gene, a VEGF-trap molecule.  We saw similar gross 
phenotypes, impaired limb use and increased ischemic appearance.  We also 
observed attenuation in adductor perfusion, which is consistent with impaired 
collateral remodeling (See Chapter 2).23 
Although we did not see significance in the plantar perfusion deficit in the 
Cre-recombinase treated animals, we have reason to believe that further 
optimization of the electroporation protocol will allow us to measure a significant 
change.  These experiments were performed before the report demonstrating 
differences in gene expression in various IRES constructs was published.  With 
the re-engineering of Cre into the high expressing plasmid pIRES3, repetition of 
the experiment will likely see positive results. 
The addition of luciferase as a reporter gene allowed us to serially 
examine plasmid expression in the same mice over an extended time period.  
Future studies will allow the normalization of various parameters to luciferase 
expression, such that high and low expressers can be distinguished.  While we 
were able to measure attenuation in adductor perfusion, we saw no difference in 
plantar recovery in mice receiving FltIgG or LacZ in the adductor.  The mice used 
were C57BL/6 and it has been previously shown that this strain has a robust 
angiogenic response to femoral artery ligation.21-23  It is possible that in the 
absence of FltIgG in the calf, that a robust angiogenic response occurred to 
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increase the Doppler perfusion signal.  Histological studies will need to be 
performed on calf and adductor tissues to verify this possibility.  
In conclusion, we have identified a positive role for paracrine VEGF in 
arteriogenesis.  To understand the biology of collateral growth, it will be 
necessary to study the contributions of a host of endogenous molecules.  With 
the increasing availability of conditional mouse strains and peptide/protein 
inhibitors coupled with in vivo electroporation, we can now temporally and 
spatially study collateral growth.  Plasmid constructs used in this study use the 
CMV promoter to drive non-cell selective expression.  Future studies are not 
restricted to non-selective expression.  Cell-type specific promoters can be used 
to drive cell specific deletion or expression of molecules of choice.  The field is no 
longer limited by mouse models that die embryonically or factors that exhibit 







Figure 3.1:  Immunofluorescence of VEGFhi/+ mice reveal increased -
galactosidase staining around remodeling collateral artery.  -galactosidase 
expression recapitulates VEGF expression.145  Gracilis collateral at d7 post-
ligation (a-c), and at d0 (d-f).  Arteriole in adductor magnus muscle (g-i).  






Figure 3.2:  In vivo electroporation of plasmid encoding -galactosidase 
yields long-term and restricted gene expression.  (a) Diagram depicting the inner 
thigh (adductor).  Site of hyaluronidase and plasmid injections are shown as 
asterisks.  (b-e) Two separate mice injected and electroporated with pIRES-LacZ 
and stained with X-gal at d7 post-electroporation (b) and d21 post-
electroporation (c,d).  X-gal staining is excluded from the calf and is restricted to 





Figure 3.3:  VEGFloxP/loxP mice receiving electroporation of plasmid 
expressing Cre recombinase into the adductor show increased ischemic 
appearance, poor use, and impaired recovery of plantar perfusion.  (a) 
Appearance score.  Scale: 0=normal, 1=cyanosis or loss of nail(s), 2=partial or 
complete atrophy of digit(s), 3=partial atrophy of fore-foot; n=9 per data-point.  
(b) Use score.  Scale: 0=normal, 1=no toe flexion/spreading, 2=no plantar 
flexion, 3=foot dragging; n=9 per data point.   Laser Doppler perfusion images of 
plantar foot (c) and ventral adductor (d) with region of interest (ROI).  
Quantification of plantar perfusion (e) and adductor perfusion (f) measured over 
ROI.  Data are mean±SEM for this and other figures.  Two-way ANOVA followed 





Figure 3.4:  Electroporation induces an ―inflammatory‖ hyperemic 
response in the adductor that is not ameliorated by anti-inflammatory drugs.  
Raw perfusion values in the ligated adductor (a) and non-ligated adductor (b).  
Time of electroporation is depicted by arrow and EP.  (c)  Raw perfusion values 
following administration of 0.2 mg/ml Ibuprofen (IBU) in drinking water 7 days 
before electroporation and throughout the time course.  Two-way ANOVA 
followed by Dunn-Bonferonni corrected t-Test, #p<0.05 pCre-IRES-LacZ vs. 






Figure 3.5:  In vivo electroporation of a plasmid expressing luciferase 
allows for non-invasive imaging of plasmid expression over 21 days.  (a-d) 
Pseudo-colored images of integrated photons at specified time points in the 





Figure 3.6:  Adductor expression of FltIgG leads to impaired limb use, 
increased ischemic appearance, attenuated adductor perfusion, but no changes 
in plantar perfusion.  Appearance (a) and Use (b) scores of mice receiving pLuc-
IRES3-LacZ (control) or pLuc-IRES3-FltIgG.  See Fig. 3.6 for scales.  Plantar 
perfusion ratio (c) and adductor perfusion ratio (d) with times of electroporation 
indicated by arrows.  EP=electroporation.  Two-way ANOVA followed by Dunn-
Bonferonni corrected t-Test, *p<0.05, **p<0.01; pLuc-IRES3-LacZ vs. pLuc-





Figure 3.7:  Whole blood leukocyte counts following electroporation and 
femoral artery ligation.  Data are expressed as percentage of total white blood 
cell counts for lymphocytes (a), granulocytes (b), and monocytes (c).
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 CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
 
VEGF EXPRESSION AND ARTERIOGENESIS 
Early studies by Couffinhal and colleagues have shown that VEGF is 
upregulated in ischemic calf muscles in a hindlimb ischemia model.116  In addition 
to skeletal muscle, VEGF expression was also seen in lymphocytes, monocytes 
and endothelial cells in the ischemic calf.  Whether this expression pattern was 
recapitulated in the adductor (ie, surrounding growing collaterals) was not known.  
I have shown that VEGF is expressed selectively in skeletal myocytes 
surrounding a remodeling collateral artery.  This expression was exclusive to 
remodeling collaterals in that there was little or no expression in non-remodeling 
collaterals and other arterioles.  There was also evidence of peri-collateral CD45+ 
leukocytes expressing VEGF.  It was difficult to ascertain VEGF expression in 
other cell types.  High resolution confocal microscopy will be necessary to 
determine what other cell types express VEGF in the context of a remodeling 
collateral. 
Additionally, I have shown a unique expression pattern of VEGF isoforms 
in the adductor compared to the ischemic calf.  There was selective upregulation 
of the soluble VEGF isoform, VEGF120, in the ischemic calf.  This is consistent 
with properties of a soluble isoform in mediating extensive angiogenesis in the 
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calf and for mobilizing leukocytes in the bone marrow.  In the adductor, the 
opposite pattern was observed.  The high molecular isoforms, VEGF164 and 
VEGF188, were selectively upregulated in the adductor.  The physical properties 
of these heparin binding isoforms allow for restricted and localized expression to 
allow for tighter control of VEGF signaling.  The resolution of our qRT-PCR 
experiments does not allow us to define precise cellular localization, however it 
does demonstrate that different physiological processes are eliciting different 
VEGF expression patterns.  In situ hybridization is a technique that can identify 
the cell types that express VEGF mRNA.  The use of locked nucleic acid (LNA) 
probes may allow one to discriminate the specific isoforms that are expressed. 
One intriguing question that remains to be answered is how different 
physiological processes affect mRNA splicing.  The molecular mechanism of 
alternative splicing has been well studied, however mechanisms describing 
tissue specific splicing patterns or splicing patterns altered by different 
physiological processes is less well understood.  A recent study has described 
hypoxia as a regulator of mRNA splicing by altering the expression of 
components of the splicing machinery.168  It is likely that hypoxia in the ischemic 
calf muscle is driving an alternative splicing pattern of VEGF.  MicroRNA’s have 
recently been identified as modifiers of gene expression.  Indeed, microRNA ’s 
have shown to promote tissue specific pre-mRNA splicing.169  In vitro 
experiments with cells that express VEGF may be more amenable to study the 




GENETIC CONTRIBUTION TO ARTERIOGENESIS 
Analysis of arteriogenesis in genetic mouse models requires the maturity 
of mice into adults.  Unfortunately, many mutant mouse models of genes that 
regulate angiogenesis are embryonic lethal and thus cannot be studied for their 
role in arteriogenesis.  However, the increasing incidence of conditionally 
targeted mutants together with tissue specific Cre lines, now allows one to study 
molecules in a tissue specific manner for their effects on collateral growth. 
In a recent study, our laboratory has reported strain specific differences in 
arteriogenesis.  C57BL/6 mice had increased collateral remodeling and perfusion 
recovery than BALB/c mice.23  In addition, C57BL/6 mice had numerous 
collaterals in skeletal muscle, intestine, and pia while BALB/c mice had fewer.23  
Genetic dissection of factors that regulate arteriogenesis and collateral 
development can be facilitated by analyzing various crosses of these mice.  
Indeed, mRNA expression quantitative trait loci (eQTL) analysis of VEGF has 
shown that C57BL/6 has polymorphism on or near the Vegfa locus that is 
associated with increased VEGF expression, compared to BALB/c.  Given this 
association of VEGF expression with arteriogenesis and collateral density, I 
wanted to test the role of genetic perturbations of VEGF and its receptors in 
collateral artery growth in ischemic disease and collateral artery development in 
normal tissue. 
Homozygous deletion of VEGFR-1 and VEGFR-2 is embryonic lethal so it 
is difficult to study their roles in arteriogenesis.  In Chapter 2, I showed that 
heterozygosity of VEGFR-1 impaired arteriogenesis while VEGFR-2 
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heterozygosity had no effect on recovery.  Due to the high kinase activity of 
VEGFR-2, my studies do not rule out a positive role for VEGFR-2.  It is possible 
that sufficient receptor density exists to allow proper signaling through VEGFR-2 
and thus demonstrate no adverse effects of femoral artery ligation.  Conditional 
mice have now been generated for both receptors.139, 170  Breeding these mice to 
tissue specific Cre-recombinase driver strains will be important to determine the 
cells and the receptors that are required to mediate arteriogenesis. 
VEGF heterozygosity leads to early embryonic lethality,132, 133 thus the 
study of the genetic contribution of this gene is impossible in adults.  However, 
mutant mouse strains have been created that confer hypermorphic or 
hypomorphic VEGF phenotypes.130, 131, 145  Using these mice, I was able to show 
that VEGF hypomorphs, VEGFlo/+, have impaired arteriogenesis and perfusion 
recovery.  No increase in arteriogenesis was observed in VEGF hypermorphs, 
VEGFhi/+.  However, it is possible that a ceiling effect was reached, such that 
greater increases in VEGF could not further augment arteriogenesis as that seen 
in wild-type mice.  In addition, we observed a VEGF genotype – collateral 
number relation, such that VEGFhi/+ mice had more collaterals and VEGFlo/+ mice 
had fewer.  Together these observations support a genetic role of VEGF in 
mediating arteriogenesis and collateral development. 
 
PARACRINE VEGF IS REQUIRED FOR ARTERIOGENESIS 
Systemic VEGF administration or inhibition has provided evidence for a 
positive role in arteriogenesis.  However, VEGF’s actions systemically can 
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confound any direct action on collaterals.  I thus designed experiments to locally 
restrict VEGF inhibition only to the thigh where arteriogenesis takes place.  Using 
conditional VEGF mice164, I electroporated a plasmid expressing Cre-
recombinase to the mouse thigh.  Thigh selective VEGF deletion resulted in 
impaired limb use and increased ischemic appearance over LacZ control 
electroporated mice.  Adductor VEGF deletion also impaired plantar perfusion 
recovery.  This data suggests that resident cells in the thigh, including skeletal 
muscle, collateral vessel wall cells, and resident leukocytes are important 
contributors of VEGF and mediate arteriogenesis and perfusion recovery. 
In a parallel experiment, I electroporated a plasmid expressing the VEGF-
trap molecule, FltIgG into the thigh of C57BL/6.  This mouse strain was chosen 
for its characterization as a robust model of arteriogenesis.21-23  Inhibition of 
arteriogenesis was most likely to be detected in this strain.  Indeed, mice 
receiving FltIgG in the thigh experienced greater ischemic appearance and 
impaired limb use.  Additionally, attenuated adductor perfusion was observed 
while plantar perfusion recovery was unaffected.  A benefit of FltIgG expression 
in the adductor, is that it will bind to all VEGF produced in the thigh as well as 
VEGF that is delivered to the thigh from the circulation.  It is possible that 
increased angiogenesis in the calf compensated for reduced collateral growth in 
the thigh to give no change in plantar perfusion measurements.  Histological 
measurements are necessary to distinguish between reduced collateral growth 
and increased angiogenesis. 
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The technique of in vivo electroporation has allowed targeted inhibition, 
both spatially and temporally, of VEGF in order to examine its role in 
arteriogenesis.  This technology does not need to be restricted to VEGF.  In vivo 
electroporation opens up new possibilities to study the paracrine role of a host of 
growth factors, cytokines, and matrix proteins.  Plasmid electroporation can be 
combined with conditional mouse mutants, tissue specific promoters and 
performed at various time points during collateral remodeling to more precisely 
pin-point the responsible molecules and the time at which they act.  By 
understanding the precise biological mechanisms of arteriogenesis including cell 
types, molecules, and temporal progression, researchers can rationally design 
improved therapies to treat patients with ischemic vascular disease. 
 
FUTURE DIRECTIONS 
The elucidation of genetic factors regulating collateral growth in ischemia 
and collateral development in the embryo or adult is the next frontier in 
arteriogenesis research.  The model system of the BALB/c and C57BL/6 
provides strong tools to dissect these factors.  eQTL analysis has the potential to 
identify novel pathways that determine collateral development.  The current 
eQTL database for BALB/c and C57BL/6 crosses are limited.  We have the ability 
to expand this database and probe additional factors with ischemic and non-
ischemic calf muscle and ligated and non-ligated adductor muscles.  In addition, 
genetic mapping experiments are underway to identify loci linked to collateral 
density and growth. 
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The addition of a stroke model of middle cerebral artery occlusion has 
enabled us to visualize collateral growth and hemodynamics that was not 
possible with the femoral artery ligation model.  The stroke model is amenable to 
manipulation of molecular pathways identified in eQTL and QTL analysis of 
BALB/c and C57BL/6 crosses. 
The identification of VEGF as the first molecule implicated in establishing 
collateral development is the first step in understanding the complex process of 
collateral growth and development.  Undoubtedly, elucidation of novel pathways 
utilizing genetic crosses will further our knowledge and potentially enable 
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